CONFIDENTIAL
30-JAN-2018 1Clinical Study Protocol
Sponsor:
GlaxoSmithKline Biologicals SA
Rue de l‚ÄôInstitut 89, 1330 Rixensart, Belgium
Primary Study vaccine !GlaxoSmithKline (GSK) Biologicals‚Äô lyophilized 
formulation of the Herpes Zoster (HZ) subunit 
(HZ/su) vaccine (GSK1437173A)
Other Study vaccine Licensed pneumococcal polysaccharide conjugate 
vaccine (13-valent, adsorbed), Prevenar13‚Ñ¢.
eTrack study number and 
Abbreviated Title204487 (ZOSTER-059 PRI)
Investigational New Drug 
(IND) numberBB-IND-13857
EudraCT number 2017-001220-22
Date of protocol Final Version 2: 26 September 2017
Date of protocol 
amendmentAmendment 1 Final: 30 October 2017
Amendment 2 Final: 30 January 2018
Title Immunogenicity and safety study of GSK Biologicals‚Äô 
Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years 
and older.
Detailed Title A Phase IIIB, randomized, open-label, multicenter 
clinical trial to assess the immunogenicity and safety of GSK Biologicals‚Äô Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older.
Co-ordinating author , Scientific Writer, contractor for GSK 
Biologicals
Contributing authors
(Amended 30 January 2018)! , Clinical and Epidemiology 
Scientist
! , Clinical and Epidemiology 
Project Lead
! , Clinical and Epidemiology 
Project Leader
! , Project Statistician
! , Lead Statistician
_3URWRFRO$PHQGPHQW-DQ_70)_
PPDPPD
PPD
PPD
PPD
PPD
CONFIDENTIAL
204487 (ZOSTER-059 PRI)
Protocol Amendment 2 Final
30-JAN-2018 2eTrack study number and 
Abbreviated Title204487 (ZOSTER-059 PRI)
Investigational New Drug 
(IND) numberBB-IND-13857
EudraCT number 2017-001220-22
Detailed Title A Phase IIIB, randomized, open-label, multicenter 
clinical trial to assess the immunogenicity and safety of GSK Biologicals‚Äô Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older.
Contributing authors
(Contd.)
(Amended 30 January 2018)! , Study Delivery Lead
! , Study Delivery Lead, Synteract
Inc. for GSK Biologicals
! , Study Delivery Associate
! , Clinical Trial Supply Manager
! , Clinical Safety representative
! , Clinical Safety 
representative
! , Study Data Manager (Tata 
Consultancy Services for GSK Biologicals)
!  Study Data Manager (Tata 
Consultancy Services for GSK Biologicals)
! , Oversight Data Manager
! , Global Regulatory Affairs
! , Global Regulatory Affairs
! , United States Regulatory Affairs
! , Global Patents
! , Global Medical Affairs
! , Clinical Readout Team Lead
! , Laboratory Study Manager
GSK Biologicals‚Äô Protocol DS v 15.0
¬©2017 -2018 GSK group of companies or its licensor_3URWRFRO$PHQGPHQW-DQ_70)_
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 3Protocol Amendment 2Sponsor Signator y Approval
eTrack study number and 
Abbreviated Title204487 ( ZOSTER -059 PRI)
IND number BB-IND-13857
EudraCT number 2017 -001220-22
Date of protocol amendment Amendment 2 Final: 30 January  2018
Detailed Title A Phase IIIB, randomized, open -label, multicenter
clinical trial to assess the immunogenicit y and safety 
of GSK Biologicals‚Äô Herpes Zoster vaccine 
GSK1437173A when co -administered with 
Prevenar13 in adults aged 50 y ears and older.
Sponsor signatory
(Amended 30 January 2018)Anne Schuind
Clinical and Epidemiology Project Leader, 
Zoster Program, US Research and Development 
Center (RDC)
Signature
Date204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 4Protocol A mendment 2Rationale
Amendment number: Amendment 2
Rationale/background for changes:
Major change:
ÔÇ∑This amendment is in response to the Center for Biologics Evaluation and 
Research (CBER )comments on Protocol Amendment 1, received on 09-January-
2018 ,requesting clarification on 1. the adjustment for baseline titers in the 
computation of the Multiplex Opsonophagocy tosis Assay (MOPA )Geometric 
Mean Titers (GMT) ratios (Section 10.7.2) and 2. time points for primary  
evaluations on co -primary  immunogenicit y objectives (Section 10.10.1).
Other changes:
ÔÇ∑The tradename for pneumococcal polysaccharide conjugate vaccine (13 -valent adsorbed)
in Canada has been corrected to Prevnar13 from Prevenar13.
ÔÇ∑The laboratory to be used for MOPA testing has been selected and is presented in 
Appendix B.
ÔÇ∑A typographical error in the estimated number of subjects in each age strata and 
study  group has been corrected. Table 4 reflects the correct number of subjects for 
age stratification.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 5Protocol Amendment 2Investigator Agreement
I agree:
ÔÇ∑To conduct the stud y in compliance with this protocol, an y future protocol 
amendments or protocol administrative changes, with the terms of the clinical trial 
agreement and with an y other study  conduct procedures and/or stud y conduct 
documents provided b y GlaxoSmithKline (GSK) Biologicals.
ÔÇ∑To assume responsibility for the proper conduct of the study  at this site.
ÔÇ∑That I am aware of, and will comply  with, ‚ÄòGood Clinical Practice‚Äô (GCP) and all 
applicable regulatory  requirements.
ÔÇ∑To ensure that all persons assisting me with the study  are adequatel y informed about 
the GSK Biologic als‚Äô study vaccine(s) and other study -related duties and functions 
as described in the protocol.
ÔÇ∑To acquire the reference ranges for laboratory  tests performed locall y and, if required 
by local regulations, obtain the laboratory ‚Äôs current certification or Quality  
Assura nce procedure manual.
ÔÇ∑To ensure that no clinical samples (including serum samples) are retained onsite or 
elsewhere without the approval of GSK Biologicals and the express written informed 
consent of the subject and/or the subject‚Äôs leg ally acceptable repr esentative.
ÔÇ∑To perform no other biological assay s on the clinical samples except those described 
in the protocol or its amendment(s).
ÔÇ∑To co -operate with a representative of GSK Biologicals in the monitoring process of 
the study  and in resolution of queries about the data.
ÔÇ∑That I have been informed that certain regulatory  authorities require the sponsor to 
obtain and supply , as necessary , details about the investigator‚Äôs ownership interest in 
the sponsor or the investigational vaccine(s) and more generall y about his/her 
financial ties with the sponsor. GSK Biologicals will use and disclose the 
information solely  for the purpose of comply ing with regulatory  requirements.
Hence I:
ÔÇ∑Agree to suppl y GSK Biologicals with an y necessary  information regarding 
ownershi p interest and financial ties (including those of my  spouse and dependent 
children).
ÔÇ∑Agree to promptl y update this information if an y relevant changes occur during the 
course of the stud y and for one year following completion of the study. 
ÔÇ∑Agree that GSK Biologicals may  disclose any  information it has about such 
ownership interests and financial ties to regulatory authorities.
ÔÇ∑Agree to provide GSK Biologicals with an updated Curriculum Vitae and other 
documents required b y regulatory  agencies for this stud y.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 6eTrack study number and 
Abbreviated Title204487 ( ZOSTER -059 PRI)
IND number BB-IND-13857
EudraCT number 2017 -001220-22
Date of protocol amendment Amendment 2 Final: 30 January  2018
Detailed Title A Phase IIIB, randomized, open -label, multicenter 
clinical trial to assess the immunogenicit y and safety 
of GSK Biologicals‚Äô Herpes Zoster vaccine 
GSK1437173A when co -administered with 
Prevenar13 in adults aged 50 y ears and older.
Investigator name
Signature
Date
Leiter derklinischen Pr√ºfung 
name, function and title
Signature
Date204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 7Sponsor Information
1.Sponsor
GlaxoSmithKline Biologicals
Rue de l‚ÄôInstitut 89, 1330 Rixensart, Belgium
2.Sponsor Medical Expert for the Study
Refer to the local study  contact information document.
3.Sponsor Study Monitor
Refer to the local study  contact information document.
4. Sponsor Study Contact for Reporting of a Serious Adverse Event
GSK Biologicals Central Back -up Study  Contact for Reporting SAEs: refer to protocol 
Section 8.4.2204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 8SYNOPSIS
Detailed Title A Phase IIIB, randomized, open -label, multicenter clinical 
trial to assess the immunogenicity  and sa fety of GSK 
Biologicals‚Äô Herpes Zoster vaccine GSK1437173A when co -
administered with Prevenar13 in adults aged 50 years and 
older.
Indication Prevention of Herpes Zoster (HZ) and related complications 
in adults ‚â•50 y ears of age (YOA) and immunocompromized 
(IC) adults ‚â•18 YOA .
Rationale for the 
study and study 
designVaricella -zoster virus (VZV) causes two distinct diseases. 
Varicella (chickenpox) occurs shortl y after primary VZV 
infection and is characterized by  systemic illness and a w idely 
disseminated rash. Herpes zoster (HZ; shingles) occurs when 
VZV reactivates from latency  and t ypically manifests as a 
localized, dermatomal rash.
The typical HZ rash usually  lasts 2 to 4 weeks and is ty picall y 
accompanied b y pain and pruritus. The mo st common 
complication of HZ is postherpetic neuralgia (PHN), defined 
as pain that persists after the resolution of the HZ rash. 
Declining VZV -specific immune responses with older age are 
a clear risk factor for developing shingles and PHN.
The objective of the current phase III study  is to assess 
immunogenicit y, reactogenicity and safety of GSK 
Biologicals‚Äô HZ vaccine when its first dose is co- administered 
with a pneumococcal poly saccharide conjugate vaccine 
(Prevenar13 ) in adults aged ÔÇ≥50 Y OA, as compared to the 
control group where the two HZ/su doses are administered 
subsequent to Prevenar13.
The twoparallel arms study  design was selected to allow an 
assessment of the immunogenicity , reactogenicit yand safet y
of HZ/su and Prevenar13 vaccin es when they  are co -
administered and when administered separatel y in a staggered 
schedule ( Prevenar13 followed by  HZ/su).
Objectives Co-Primary
ÔÇ∑To determine the vaccine response rate (VRR) to HZ/su 
(based on humoral immune response) one month after the 
second vaccine dose, when the first dose of HZ/su is co -
administered with Prevenar13 (Co-Ad group) .*204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 9Criterion to be used: 
The objective is met if the lower limit (LL) of the 95% CI 
of the VRR for anti -gE antibody concentrations in the Co-
Ad group one month after the second vaccine dose is 
‚â•60%.
* The VRR for anti -gE is defined as the percentage of subjects 
who have at least: a 4 -fold increase in the anti -gE antibodies 
concentration as compared to the pre- vaccination anti -gE 
antibodies concentration, for subjects who are seropositive at 
baseline, or, a 4 -fold increase in the anti -gE antibodies 
concentration as compared to the anti- gE antibodies cut- off 
value for seropositivity , for subjects who are seronegative at 
baseline.
If the above objective is met in the Co -Ad group, then the 
following objective will be evaluated:
ÔÇ∑To demonstrate non -inferiority  of the humoral immune 
response to two doses of HZ/su at one month after the last 
vaccine dose, when the first dose of HZ/su is co-
administer ed with Prevenar13 (Co-Ad group) compared 
to when two doses of HZ/su are administered subsequent 
to Prevenar13 (Control Group).
Criterion for non- inferiority: 
One month after the last vaccine dose in each study 
group, the upper limit (UL) of the 95% confidence 
interval (CI) for the anti- gE antibodies Geometric Mean 
Concentration (GMC) ratio between the Control group 
and the Co- Ad group is <1.5.
If the above non -inferiority  objective is met, then the 
following objective will be evaluated:
ÔÇ∑To demonstr ate non- inferiority  of the humoral immune 
response to Prevenar13 at one month after the vaccine 
dose, when Prevenar13 is co-administered with the first 
HZ/su dose (Co -Ad group) compared to when 
Prevenar13 is administered separatel y from HZ/su 
(Control group), for the 13 seroty pes included in 
Prevenar13 anal yzed sequentially .
Criterion for non- inferiority: 
One month after the Prevenar13 vaccine dose in each 
study group, the UL of the 95% CI for each individual 
pneumococcal conjugate serotype Geometric Mea n Titer 
(GMT) ratio of the Control group over the Co- Ad group 
is <2.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 10For the co- primary  objectives, fixed sequence testing which 
allows for full alpha propagation in pre -ordered hypotheses 
families will be used.
Secondary
ÔÇ∑To evaluate the safet y and rea ctogenicity  following 
administration of HZ/su and Prevenar13 vaccines, up to 
one month post last vaccination and during the whole 
follow -up period, in the Control group and the Co -Ad 
group.
Study design ÔÇ∑Experimental design : Phase IIIB, open -label, 
randomized, controlled, multi- centric , and multi -country , 
with two parallel groups. 
ÔÇ∑Duration of the study : The intended duration of the 
study  per subject is approximately  14 months for subjects 
from the Co- Ad group and approximately  16 m onths for 
subjects from the Control group.
ÔÄ≠Epoch 001: Primary starting at Visit Day  1 and 
ending with the phone contact at Month 16.
ÔÇ∑Primary completion date (PCD) : Visit Month 5. 
ÔÇ∑End of Study (EoS ): Last testing results released of 
samples collected at Visit Month 3 (Co- Ad group) or at 
Visit Month 5 (Control group).
ÔÇ∑Study groups :
Synopsis Table 1 Study  groups and epochs foreseen in the study
Study groups Number of subjects AgeEpochs
Epoch 001
Co-Ad 456 ÔÇ≥50 years x
Control 456 ÔÇ≥50 years x
Synopsis Table 2 Study  groups and treatment foreseen in the study
Treatment name Vaccine/Product name Study Groups
Co-Ad Control
HZ/su VZV gE X x
AS01B x x
Prevenar13 Prevenar 13 x x204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 11ÔÇ∑Control : active control .
ÔÇ∑Vaccination schedule(s):
Co-Ad Group: 
ÔÄ≠at Visit Day 1: first dose of HZ/su and one dose of 
Prevenar13 ,
ÔÄ≠at Visit Month 2: second dose of HZ/su. 
Control Group: 
ÔÄ≠at Visit Day  1: one dose of Prevenar13, 
ÔÄ≠at Visit Month 2: first dose of HZ/su,
ÔÄ≠at Visit Month 4: second dose of HZ/su.
ÔÇ∑Treatment allocation : Subjects to be randomized in a 
1:1 ratio at Visit Day  1 to either Co -Ad or Control group. 
Subjects in each group will be stratified by  age with the 
following approximate distribution (not less than 25% in 
each age strata):
ÔÄ≠171 subjects in the 50- 59 YOA stratum, 
ÔÄ≠171 subjects in the 60- 69 YOA stratum, and
ÔÄ≠114 subjects in the ‚â• 70 YOA stratum.
ÔÇ∑Blinding :open -label
Synopsis Table 3 Blinding of study  epochs
Study Epochs Blinding
Epoch 001 open
ÔÇ∑Sampling schedule : Blood samples (approximately  8 mL) 
will be collected for each group, as described below.
For Co -Ad group : 
ÔÄ≠at Visit Day  1 to assess baseline antibody  
concentrations/titers with respect to Prevenar13 and 
HZ/su vaccine antigens, prior to vaccination, 
ÔÄ≠at Visit Month 1 to assess humoral immune response 
with respect to Prevenar13 vaccine antigens, 1 month 
post-vaccination,
ÔÄ≠at Visit Month 3 to asses s humoral immune response 
with respect to the HZ/su vaccine antigen, 1 month 
post-second vaccination dose.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 12For Control group:
ÔÄ≠at Visit Day  1 to assess baseline antibody  
concentrations/titers with respect to Prevenar13 vaccine 
antigens, prior to vaccinati on, 
ÔÄ≠at Visit Month 1 to assess humoral immune response 
with respect to Prevenar13 vaccine antigens, at 1 month 
post-vaccination,
ÔÄ≠at Visit Month 2 to assess baseline antibod y 
concentrations/titers with respect to the HZ/su vaccine 
antigen, prior to first v accination dose,
ÔÄ≠at Visit Month 5 to assess humoral immune response 
with respect to the HZ/su vaccine antigen, at 1 month 
post-second vaccination dose.
For both groups:
ÔÄ≠A urine specimen will be collected from all female 
subjects of childbearing potential a t Visit Day  1 and 
Visit Month 2 for Co- Ad group, and at Visit Day  1, 
Visit Month 2 and Visit Month 4 for the Control group. 
If a serum pregnancy  test instead of a urine pregnancy  
test is required b y country, local or ethics committee 
regulations, a blood s ample will be collected from 
women of childbearing potential at these visits and will 
be used for the test as per local guidance.
Note: the result of the urine/serum pregnancy  test must be 
obtained before vaccination.
ÔÇ∑Type of study : self-contained .
ÔÇ∑Data collection : Electronic Case Report Form ( eCRF ).
Safety monitoring : An internal GSK Safet y Review Team 
(SRT) part of the HZ/su vaccine project will oversee the safet y 
of the study  subjects on a regular basis. Serious Adverse Events 
(SAEs) and Adverse Even ts (AEs) including p IMDs will be 
reviewed b y the SRT at regular intervals together with data 
from other ongoing HZ/su vaccine studies. An y potential safet y 
concern related to conduct of the study  will be escalated to 
higher internal decision boards as per internal GSK process.
Number of subjects Target enrollment will be approximately  912 eligible subjects, 
to obtain 820 evaluable subjects (410 in each study group).204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 13Endpoints Primary
ÔÇ∑HZ/su immunogenicit y:
ÔÄ≠Vaccine response for anti -gE humoral immunogenic ity, 
as determined b y ELISA, in subjects from the Co -Ad 
group at one month post- dose 2, at Visit Month 3.
ÔÄ≠Anti- gEantibody  concentrations as determined b y 
ELISA at one month post- dose 2, at Visit Month 3 for 
the Co -Ad group and Visit Month 5 for the Control 
group.
ÔÇ∑Pneumococcal vaccine immunogenicit y:
ÔÄ≠Anti- pneumococcal antibody  titers for the 13 following 
seroty pes as determined by  MOPA at one month post -
dose at Visit Month 1: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F and 23F.
Secondary
ÔÇ∑Occurrence of solicited local and general s ymptoms : 
ÔÄ≠Occurrence, duration and intensity  of each solicited 
local sympt om within 7 day s (Day s 1 - 7) after each 
vaccination .
ÔÄ≠Occurrence, duration, intensity  and relationship to 
vaccination of each solicited general sy mptom within 7 
days (Day s 1 to 7) after each vaccination.
ÔÇ∑Occurrence of unsolicited AEs:
ÔÄ≠Occurrence, intensity  and relationship to vaccination of 
unsolicited AEs within 30 day s (Day s 1 to 30) after 
each vaccination, according to the Medical Dictionary  
for Regulatory  Activities (MedDRA) classification.
ÔÇ∑Occurrence of SAEs:
ÔÄ≠Occurrence and relationship t o vaccination of all SAEs 
from first vaccination at Day  1 up to 30 day s post last 
vaccination.
ÔÄ≠Occurrence and relationship to vaccination of all SAEs 
during the period starting after 30 day s post last 
vaccination up to study  end.
ÔÇ∑Occurrence of pIMDs:
ÔÄ≠Occurrence and relationship to vaccination of an y 
pIMDs from first vaccination at Day  1 up to 30 day s 
post last vaccination.
ÔÄ≠Occurrence of an y pIMDs during the period starting 
after 30 day s post last vaccination up to study  end.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 14TABLE OF CONTENTS
PAGE
SPONSOR INFORMATION ............................................................................................ 7
SYNOPSIS ...................................................................................................................... 8
LIST OF ABBREVIATION S........................................................................................... 22
GLOSSARY OF TERMS ............................................................................................... 25
TRADEMARKS ............................................................................................................. 30
1.INTRODUCTION .................................................................................................... 31
1.1. Background ................................................................................................ 31
1.2. Rationale for the study and study design .................................................... 32
1.3. Benefit : Risk Assessment .......................................................................... 32
1.3.1. Risk Assessment ......................................................................... 33
1.3.2. Benefit Assessment ..................................................................... 34
1.3.3. Overall Benefit: Risk Conclusion .................................................. 34
2.OBJECTIVES ......................................................................................................... 34
2.1. Co-Primary objectives ................................................................................. 34
2.2. Secondary objective ................................................................................... 35
3. STUDY DESIGN OVERVIE W................................................................................ 36
4.STUDY COHORT ................................................................................................... 39
4.1. Number of subjects/centres ........................................................................ 39
4.2. Inclusion criteria for enrolment .................................................................... 39
4.3. Exclusion criteria for enrolment ................................................................... 40
5.CONDUCT OF THE STUDY .................................................................................. 42
5.1. Regulatory and ethical considerations, including the informed 
cons ent process .......................................................................................... 42
5.2. Subject identification and randomization ..................................................... 43
5.2.1 .Subject identification .................................................................... 43
5.2.2. Randomization of treatment ......................................................... 43
Randomization of supplies .......................................... 43 5.2.2.1.
Treatment allocation to the subject ............................. 43 5.2.2.2.
5.2.2.2.1. Study group and treatment 
number allocation ................................... 43
5.2.2.2.2. Treatment number allocation for 
subsequent doses .................................. 44
5.3. Method of blinding ...................................................................................... 44
5.4. General study aspects ................................................................................ 44
5.5. Suspected HZ cases ................................................................................... 45
5.6. Outline of study procedures ........................................................................ 45
5.7. Detailed description of study procedures .................................................... 48
5.7.1. Informed consent ......................................................................... 48
5.7.2. Check inclusion and exclusion criteria ......................................... 49204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 155.7.3. Collect demographic data ............................................................ 49
5.7.4. General medical history ............................................................... 49
5.7.5. History directed physical examination .......................................... 49
5.7.6. Pregnancy test ............................................................................. 49
5.7.7. Check contraindications, warnings and precautions to 
vaccination ................................................................................... 49
5.7.8. Assess pre-vaccination body temperature ................................... 50
5.7.9. Study group and treatment number allocation .............................. 50
5.7.10. Sampling ...................................................................................... 50
Blood sampling for immune response 5.7.10.1.
assessments .............................................................. 50
5.7.11. Study Vaccine(s) administration ................................................... 50
5.7.12. Check and record concomitant medication/vaccination and 
intercurrent medical conditions .................................................... 51
5.7.13. Recording of AEs, SAEs, pregnancies and pIMDs ....................... 51
5.7.14. Study conclusion .......................................................................... 51
5.8. Biological sample handling and analysis ..................................................... 52
5.8.1. Use of specified study materials .................................................. 53
5.8.2. Biological samples ....................................................................... 53
5.8.3. Laboratory assays ....................................................................... 53
5.8.4. Biological samples evaluation ...................................................... 55
Immunological read- outs ............................................ 55 5.8.4.1.
5.8.5. Immunological correlates of protection ......................................... 56
6.STUDY VACCINES AND A DMINISTRATION ........................................................ 57
6.1. Description of study vaccines ...................................................................... 57
6.2. Storage and handling o f study vaccine(s) ................................................... 58
6.3. Dosage and administration of study vaccines ............................................. 58
6.4. Replacement of unusable vaccine doses .................................................... 59
6.5. Contraindications to subsequent vaccination .............................................. 59
6.6. Warnings and precautions .......................................................................... 60
6.7. Concomitant medications/products and concomitant vaccinations .............. 60
6.7.1. Recording of concomi tant medications/products and 
concomitant vaccinations ............................................................. 60
6.7.2. Concomitant medications/products/vaccines that may lead 
to the elimination of a subject from per-protocol analyses ............ 61
6.8. Intercurrent medical conditions that may lead to elimination of a 
subject from per -protocol analyses ............................................................. 62
7.HEALTH ECONOMICS .......................................................................................... 62
8.SAFETY ................................................................................................................. 62
8.1. Safety definitions ........................................................................................ 62
8.1.1. Definition of an adverse event ...................................................... 62
8.1.2. Definition of a serious adverse event ........................................... 63
8.1.3. Solicited adverse events .............................................................. 64
Solicited local (injection -site) adverse events .............. 64 8.1.3.1.
Solicited general adverse ev ents................................ 65 8.1.3.2.
8.1.4. Clinical laboratory parameters and other abnormal 
assessments qualifying as adverse events or serious 
adverse events ............................................................................ 65
8.1.5. Adverse events of specific interest ............................................... 65204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 16Potential immune- mediated diseases ......................... 65 8.1.5.1.
8.2. Events or outcomes not qualifying as adverse events or serious 
adverse events ........................................................................................... 67
8.2.1. Pregnancy ................................................................................... 67
8.3. Detecting and recording adverse events, serious adverse events 
and pregnancies ......................................................................................... 68
8.3.1. Time period for detecting and recording adverse events, 
serious adverse events and pregnancies ..................................... 68
8.3.2. Post-Study adverse events and serious adverse events .............. 71
8.3.3. Evaluation of adverse events and serious adverse events ........... 71
Active questioning to detect adverse events 8.3.3.1.
and serious adverse events ........................................ 71
Assessment of adverse events ................................... 71 8.3.3.2.
8.3.3.2.1. Assessment of intensity .......................... 71
8.3.3.2.2. Assessment of causality ......................... 73
Assessment of outcomes............................................ 74 8.3.3.3.
Medically attended visits ............................................. 74 8.3.3.4.
8.4. Reporting of serious adverse events, pregnancies, and other events ......... 75
8.4.1. Prompt reporting of serious adverse events, pregnancies, 
and other events to GSK Biologicals ............................................ 75
8.4.2. Contact information for reporting serious adverse events, 
pregnancies and pI MDs ............................................................... 76
8.4.3. Completion and transmission of SAE reports to GSK 
Biologicals ................................................................................... 76
Back -up system in case the electronic 8.4.3.1.
reporting system does not work .................................. 76
8.4.4. Completion and transmission of pregnancy reports to GSK 
Biologicals ................................................................................... 77
8.4.5. Reporting of pIMDs to GSK Biologicals ........................................ 77
8.4.6. Updating of SAE, pregnancy, and pIMD information after 
removal of write access to the subject‚Äôs eCRF ............................. 77
8.4.7. Regulatory reporting requirements for serious adverse 
events .......................................................................................... 78
8.5. Follow- up of adverse events, serious adverse events, and 
pregnancies ................................................................................................ 78
8.5.1. Follow- up of adverse events and serious adverse events ............ 78
Follow- up during the study .......................................... 78 8.5.1.1.
Follow- up after the subject is discharged from 8.5.1.2.
the study ..................................................................... 78
8.5.2. Follow- up of pregnancies ............................................................. 79
8.6. Treatment of adverse events ...................................................................... 79
8.7. Subject card ................................................................................................ 79
9.SUBJECT COMPLETION A ND W ITHDRAW AL..................................................... 79
9.1. Subject completion ..................................................................................... 79
9.2. Subject withdrawal ...................................................................................... 79
9.2.1. Subject withdrawal from the study ............................................... 80
9.2.2. Subject withdrawal from study vaccine(s) .................................... 81
9.3. Extension study .......................................................................................... 81
10.STATISTICAL METHODS ...................................................................................... 81
10.1. Primary endpoints ....................................................................................... 81204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 1710.2. Secondary endpoints .................................................................................. 82
10.3. Determination of sample size ...................................................................... 82
10.4. Cohorts for Analyses .................................................................................. 84
10.4.1. Total vaccinated cohort ................................................................ 84
10.4.2. Per-protocol cohort for analysis of immunogenicity ...................... 85
10.5. Derived and transformed data ..................................................................... 85
10.5.1. Handling of missing data.............................................................. 85
10.6. Analysis of demographics ........................................................................... 85
10.7. Analysis of immunogenicity ......................................................................... 86
10.7.1. Humoral immune response .......................................................... 86
10.7.2. Statistical considerations for confirmatory objectives ................... 86
10.8. Analysis of safety ........................................................................................ 87
10.9. Interpretation of analyses ............................................................................ 88
10.10. Conduct of analyses ................................................................................... 88
10.10.1. Sequence of analyses .................................................................. 88
10.10.2. Statistical considerations for interim analyses .............................. 88
11.ADMINISTRATIVE MATTE RS............................................................................... 89
11.1. electronic Case Report Form instructions ................................................... 89
11.2. Study Monitoring by GSK Biologicals .......................................................... 89
11.3. Record retention ......................................................................................... 90
11.4. Quality assurance ....................................................................................... 90
11.5. Posting of information on publicly available clinical trial registers and 
publication policy ........................................................................................ 91
11.6. Provision of study results to investigators ................................................... 91
11.7. Data Sharing ............................................................................................... 91
12.COUNTRY SPECIFIC REQ UIREMENTS ............................................................... 92
12.1. Germany ..................................................................................................... 92
13.REFERENCES ....................................................................................................... 93204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 18LIST OF TA BLES
PAGE
Table 1 Study groups and epochs foreseen in the study ..................................... 37
Table 2 Study groups and treatment foreseen in the study ................................ .37
Table 3 Blinding of study ep ochs........................................................................ 37
Table 4 Age Stratification .................................................................................... 39
Table 5 Number of subjects required for enrolment ............................................. 44
Table 6 List of study procedures for Co -Ad Group .............................................. 45
Table 7 List of study procedures for Control Group ............................................. 47
Table 8 Intervals between study visits/contact for Co -Ad group .......................... 48
Table 9 Intervals between study visits/contact for Control group ......................... 48
Table 10 Biological samples ................................................................................. 53
Table 11 Humoral Immunity (Antibody determination) ........................................... 54
Table 12 Immunological read -outs for Co -Ad group .............................................. 55
Table 13 Immunological read -outs for Control group ............................................. 56
Table 14 Study vaccines ....................................................................................... 57
Table 15 Dosage and administratio n for the Co -Ad group ..................................... 59
Table 16 Dosage and administration for the Control group ................................... 59
Table 17 Solicited local adverse events ................................................................ 64
Table 18 Solicited general adverse events ............................................................ 65
Table 19 List of potential immune -mediated diseases ........................................... 66
Table 20 Reporting periods for collecting safety information ................................ .70
Table 21 Intensity scales for solicited symptoms in adults ..................................... 72
Table 22 Timeframes for submitting serious adverse event, pregnancy and 
other events reports to GSK Biologicals ................................................. 75
Table 23 Power to demonstrate VRR objective and non -inferiority of the 
immunogenicity of HZ/su and Prevenar13 co-administered 
compared to Control group ..................................................................... 84204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 19Table 24 GSK Biol ogicals‚Äô laboratories ................................................................ .96
Table 25 Outsourced laboratories ......................................................................... 96204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 20LIST OF FIGURES
PAGE
Figure 1 Overview of Study Design ...................................................................... 36204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 21LIST OF A PPENDICES
PAGE
APPENDIX A LABORATORY ASSAYS ....................................................................... 95
APPENDIX B CLINICAL LABORATORIES .................................................................. 96
APPENDIX C AMENDMENTS AND ADMINISTRATIVE CHANGES TO THE 
PROTO COL ........................................................................................... 97204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 22LIST OF A BBREVIATIONS
AE: Adverse event
ANCOVA: Analy sis of Covariance
AS01 B: MPL , QS21, liposome based Adjuvant Sy stem (50 ÔÅ≠g MPL  and 50 ÔÅ≠g 
QS21)
BS: Blood Sample
CBER: Center for Biologics Evaluation and Research 
(Amended 30 January 2018)
CDC: Centers for Disease Control and Prevention
CHMP: Committee for Medicinal Products for Human Use
CI: Confidence Interval
CLS: Clinical L aboratory  Sciences
Co-Ad: Co-administration
CRO: Contract Research Organization
(Amended 30 January 2018)
CSF: Cerebrospinal fluid
eCRF : Electronic Case Report Form
EGA: Estimated Gestational Age
ELISA: Enzy me-linked Immunosorbent Assay
EMA: European Medicines Agency
EoS: End of Study
eTDF: Electronic Temperature excursion Decision Form
FDA: Food and Drug Administration, United States
FU: Follow up
GCP: Good Clinical Practice
gE: VZV gly coprotein E
GMC/GMT: Geometric Mean Concentration/Titers
GSK: GlaxoSmithKline
HIV: Human Immunodeficiency  Virus
HZ: Herpes Zoster
HZ/su: Herpes Zoster subunit vaccine (50 ÔÅ≠g gE/AS01 B)
IB: Investigator‚Äôs Brochure
ICF: Informed Consent Form204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 23ICH: International Conference on Harmonization
IEC: Independent Ethics Committee
IDMC: Independent Data Monitoring Committee
IgG: Immunoglobulin G
IM: Intramuscular
IND: Investigational New Drug
IRB: Institutional Review Board
LL: Lower Limit
LMP: Last Menstrual Period
LSLV: Last Subject Last Visit
MACDP: Metropolitan Atlanta Congenital Defects Program
MATEX: MATerial EXcellence
MedDRA: Medical Dictionary  for Regulatory  Activities
MOPA : Multiplex Opsonophagocytosis Assay
MPL: 3-O-desacy l-4‚Äô-monophosphory l lipid A
PCD: Primary  Completion Date
PHN: Postherpetic Neuraligia
pIMD: Potential I mmune -Mediated Disease
PPC: Per-protocol cohort
Pre-Vacc: Pre-vaccination
QS21: Quillaja saponaria Molina, fraction 21 (purified saponin extract from 
the South American tree)
SAE: Serious Adverse Event
SAS: Statistical Analy sis Sy stem
SBIR: Randomization Sy stem on I nternet
SD: Standard Deviation
SDV: Source Document Verification
SmPC: Summary  of Product Characteristics
SPM: Study  Procedures Manual
SRT: Safety  Review Team
TVC: Total Vaccinated Cohort
UL: Upper Limit204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 24VRR: Vaccine Response Rate
VZV: Varicella -Zoster Virus
YOA: Years of Age204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 25GLOSSA RY OF TERMS
Adequate contraception: Adequate contraception is defined as a contraceptive 
method with failure rate of less than 1% per y ear when 
used consistently  and correctl y and when applicable, in 
accordance with the product label for example: 
ÔÇ∑abstinence from penile -vaginal intercourse, when this 
is their preferred and usual lifesty le,
ÔÇ∑Combined estrogen and progesterone oral 
contraceptives,
ÔÇ∑injectable progestogen,
ÔÇ∑implants of etenogestrel or levonorgestrel,
ÔÇ∑Contraceptive vaginal ring,
ÔÇ∑percutaneous contraceptive patches,
ÔÇ∑intrauterine devic e or intrauterine s ystem,
ÔÇ∑male partner sterili zation prior to the female subject‚Äôs 
entry  into the study , and this male is the sole partner 
for that subject,
The information on the male sterility  can come from 
the site personnel‚Äôs review of the subject‚Äôs me dical 
records; or interview with the subject on her medical 
history .
ÔÇ∑male condom combined with a vaginal spermicide 
(foam, gel, film, cream or suppository ),and/or 
progesterone alone oral contraceptive.
Adequate contraception does not apply  to subjects of 
child bearing potential with same sex partners, or for 
subjects who are and will continue to be abstinent from 
penile -vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle.
Adverse event: Any untoward medical occurrence in a patient or clinical 
investigation subject, temporally associated with the use 
of a medicinal product, whether or not considered related 
to the medicinal product. 
An adverse event (AE) can therefore be an y unfavourable 
and unintended sign (including an abnormal laboratory  
finding), s ymptom, or disease (new or exacerbated) 
temporally  associated with the use of a medicinal product. 
For marketed medicinal products, this also includes 
failure to produce expected benefits (i. e. lack of efficacy ), 
abuse or misuse.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 26Blinding: A procedure in which one or more parties to the trial are 
kept unaware of the treatment assignment in order to 
reduce the risk of biased study outcomes. The level of 
blinding is maintained throughout the co nduct of the trial, 
and only  when the data are cleaned to an acceptable level 
of quality  will appropriate personnel be unblinded or 
when required in case of a serious adverse event. In an 
open -label stud y, no blind is used. Both the investigator 
and the subject know the identity  of the treatment 
assigned.
Eligible: Qualified for enrolment into the study  based upon strict 
adherence to inclusion/exclusion criteria.
End of Study :
(Synonym of End of 
Trial)For studies without collection of human biologicals 
samples or imaging data EoS is the Last Subject Last 
Visit (L SLV). 
For studies with collection of Human Biologicals 
Samples or imaging data, EoS is defined as the date of the 
last testing/reading released of the Human Biological 
Samples or imaging data, re lated to primary  and 
secondary  endpoints. EoS must be achieved no later than 
8 months after L SLV.
Epoch: An epoch is a set of consecutive timepoints or a single 
timepoint from a single protocol. Epochs are defined to 
support a main purpose which is either to draw 
conclusions on subject participation or to draw a 
complete conclusion to define or precise the targeted 
label of the product. Supporting means that data collected 
at the timepoints included in an epoch must be sufficient 
to fulfil the purpose of the epoch.
Typical examples of epochs are screening, primary  
vaccinations, boosters, yearl y immunogenicity follow -
ups, and surveillance periods for efficacy  or safet y.
eTrack: GSK‚Äôs tracking tool for clinical trials.
Evaluable: Meeting all eligibility  criteria, compl ying with the 
procedures defined in the protocol, and, therefore, 
included in the per-protocol analysis (see Sections 6.7.2
and 10.4 for details on criteria for evaluability ).
Immunological correlate 
of pr otection:The defined immune response above which there is a high 
likelihood of protection in the absence of an y host factors 
that might increase susceptibility  to the infectious agent.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 27Intercurrent medical 
condition:An intercurrent medical condition is defined as a 
condition that has the capability  of confounding the 
immune response to the study  vaccine or its 
interpretation.
Investigational vaccine :
(Synonym of 
Investigational Medicinal 
Product)A pharmaceutical form of an active ingredient being 
tested in a clinical trial, including a product with a 
marketing authorisation when used in a way  different 
from the approved form, or when used for an unapproved 
indication, or when used to gain further information about 
an approved use. 
Legally acceptable 
representative:
(The terms legal 
representative or legally 
authorized 
representative are used 
in some settings.)An individual or juridical or other bod y authorized under 
applicable law to consent, on behalf of a prospective 
subject, to the subject's partic ipation in the clinical trial.
Menarche: Menarche is the onset of menses for the first time in a 
young female and is preceded by  several changes 
associated with pubert y including breast development and 
pubic hair growth. Menarche usuall y occurs within 1-2
years of breast development, thelarche. However, a y oung 
female can become pregnant before her first menses. 
Thus, a conservative definition of non- childbearing 
potential in a pre -menarcheal female is a y oung female 
who has not y et entered puberty  as evidenced b y lack of 
breast development (palpable glandular breast tissue).
Menopause: Menopause is the age associated with complete cessation 
of menstrual cy cles, menses, and implies the loss of 
reproductive potential by ovarian failure. A practical 
definiti on accepts menopause after 1 year without menses 
with an appropriate clinical profile at the appropriate age 
e.g. > 45 years.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 28Pharmacogenomics : The International Conference on Harmonization (ICH) 
E15 Guidance for Industry defines pharmacogenomics as 
Study of variation of DNA and RNA characteristics as 
related to drug or treatment response. Pharmacogenetics, 
which is a subset of pharmacogenomics, is ‚Äúthe study  of 
variations in DNA sequence as related to drug response.‚Äù 
Pharmacogenomic biomarkers include ger mline (host) 
DNA and RNA as well as somatic changes (e.g., 
mutations) that occur in cells or tissues. 
Pharmacogenomic biomarkers are not limited to human 
samples but include samples from viruses and infectious 
agents as well as animal samples. The term 
pharmacogenomic experiment includes both the 
generation of new genetic or genomic (DNA and/or 
RNA) data with subsequent anal ysis as well as the 
analysis of existing genetic or genomic data to understand 
drug or treatment response (pharmacokinetics, safety , 
efficacy  or effectiveness, mode of action). Proteomic and 
metabolomic biomarker research are not 
pharmacogenomics.
Potential Immune-
Mediated Disease:Potential immune -mediated diseases (p IMDs) are a subset 
of AEs that include autoimmune diseases and other 
inflammatory  and/or neurologic disorders of interest 
which may  or may  not have an autoimmune aetiology .
Primary completion 
date:The date that the final subject was examined or received 
an intervention for the p urpose of final collection of data 
for all primary  outcome s, whether the clinical trial was 
concluded according to the pre -specified protocol or was 
terminated.
Protocol amendment: The International Conference on Harmonisation (ICH) 
defines a protocol ame ndment as: ‚ÄòA written description 
of a change(s) to or formal clarification of a protocol.‚Äô 
GSK Biologicals further details this to include a change 
to an approved protocol that affects the safet y of subjects, 
scope of the investigation, study  design, or scientific 
integrit y of the stud y.
Protocol administrative 
change:A protocol administrative change addresses changes to 
only logistical or admin istrative aspects of the study.
Randomi zation: Process of random attribution of treatment to subjects in 
order to reduce bias of selection.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 29Self-contained study: Study  with objectives not linked to the data of another 
study .
Site Monitor: An individual assigned by the sponsor who is responsible 
for assuring proper conduct of clinical studies at one or 
more investigational sites.
Solicited adverse event: AEs to be recorded as endpoints in the clinical study . The 
presence/occurrence/intensity  of these events is actively  
solicited from the subject or an observer during a 
specified post -vaccination follow -up pe riod.
Study vaccine/product : Any investigational vaccine/product being tested and/or 
any authorized use of a vaccine/ product /placebo as a 
reference or administered concomitantly , in a clinical trial 
that evaluates the use of an investigational 
vaccine/product.
Sub-cohort: A group of subjects for whom specific stud y procedures 
are planned as compared to other subjects or a group of 
subjects who share a common characteristic (e.g. ages, 
vaccination schedule,‚Ä¶) at the time of enrolment.
Subject: Term used throughout the protocol to denote an 
individual who has been contacted in order to participate 
or participates in the clinical study , either as a recipient of 
the vaccine(s) or as a control.
Subject number: A unique number identify ing a subject, assigned to each 
subject consenting to participate in the study .
Treatment: Term used throughout the clinical study  to denote a set of 
investigational product(s) or marketed product(s) or 
placebo intended to be administered to a subject.
Treatment numbe r: A number identify ing a treatment to a subject, according 
to treatment allocation.
Unsolicited adverse 
event:Any AE reported in addition to those solicited during the 
clinical study . Also an y ‚Äòsolicited‚Äô sy mptom with onset 
outside the specified period of follow -up for solicited 
symptoms will be reported as an unsolicited adverse 
event.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 30TRADEM ARKS
The following trademarks are used in the present protocol.
Note: I n the body  of the protocol (including the sy nopsis), the names of the 
vaccines/products and/or medications will be written without the superscript sy mbol ‚Ñ¢ 
or ¬Æ and in italics.
Trademarks of the GSK group of companies Generic description
Shingrix Zoster Vaccine Recombinant, Adjuvanted
Trademarks not owned by the GSK group of 
companies Generic description
Prevenar13 (Trade name for Germany and 
Estonia)/ Prevnar13 Trade name forCanada 
andUnited States)*
Wyeth Pharmaceuticals Inc./Pfizer Inc .Pneumococcal polysaccharide conjugate 
vaccine (13 -valent adsorbed)
Pneumovax 23 (Trade name for Canada, 
Colombia, Germany and United States)/ 
Pneumo 23 (Trade name for Estonia)
Merck & Co., Inc.Pneumococcal polysaccharide conjugate 
vaccine (23 -valent adsorbed)
* For clarity and consistency, the pneumococcal vaccine has been writte n as Prevenar13 throughout the document
(Amended 30 January 2018 )204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 311. INTRODUCTION
1.1. Background
Varicella -zoster virus (VZV) causes two distinct diseases. Varicella (chickenpox) occurs 
shortly  after primary  VZV infection and is characterized by  systemic illness and a widel y 
disseminated rash. Herpes zoster (HZ; shingles) occurs when VZV reactivates from 
latency  and t ypicall y manifests as a localized, dermatomal rash.
The typical HZ rash usually  lasts 2 to 4 weeks and is ty picall y accompanied by pain and 
pruritus. The most common complication of HZ is postherpetic neuralgia (PHN), defined 
as pain that persists after the resolution of the HZ rash. Declining VZV -specific immune 
responses with older age are a clear risk factor for developing shingles and PHN 
[Dworkin , 2007; National Network for Immunization I nformation (NNii) , 2008].
About half of all HZ cases occur in individuals over the age of 60, and individuals who 
reach 85 YOA have a 50% chance of having HZ during their lifetime [ Oxman , 2005, 
Chua , 2010]. The risk of developing PHN varied from 5% to more than 30% depending 
on the study  design and age distribution [ Kawai , 2014]. Since the loss of VZV-specific T-
cell responses as a result of aging is associated with a heightened susceptibility  to HZ, 
vaccination is considered as a means to reduce the risk of HZ in older adults [ Oxman, 
2005; Sperber , 1992].
GlaxoSmithKline (GSK) Biologicals‚Äô va ccine (Shingrix ) for the prevention of HZ is a 
recombinant subunit (su) vaccine consisting of VZV gl ycoprotein E (gE) as antigen and 
an adjuvant s ystem AS01 B.It has been evaluated in several studies in healthy  adults and 
shown to elicit strong cellular and humoral immune responses. The safet y and 
reactogenicity  profile of the study vaccine was also acceptable . Based on phase II data 
from the antigen dose -rangin g stud y ZOSTER -003 [ Chlibek , 2014], and the adjuvant 
dose comparison stud y ZOSTER -010 [ Chlibek , 2013], a gE antigen dose of 50 ¬µg and 
the adjuvant sy stem AS01 Bwere selected for the final vaccine formulation. Henceforth in 
the document, the final vaccine formulation will be referred to as HZ/su. 
Two large pi votal phase III trials, ZOSTER -006 (also referred to as ZOE- 50) in subjects 
‚â•50 YOA and ZOSTER -022 (also referred to as ZOE- 70) in subjects ‚â•70 YOA, 
evaluated the vaccine efficacy  and safet y of HZ/su. These placebo- controlled trials 
enrolled more than 30,0 00 subjects who received either HZ/su or placebo on a 0, 2- month 
schedule. The final anal ysis of the ZOSTER -006 primary  efficacy  objective demonstrated 
that the vaccine is highl y efficacious in adults ‚â•50 YOA, with 97.2% (95% confidence 
interval [CI ] of 93.7 - 99.0) overall efficacy  against HZ. In addition, vaccine efficacy  
against HZ was between 96.6% and 97.9% for all pre- specified age groups (50 -59, 60 -69 
and ‚â•70 YOA) [ Lal, 2015]. The results from ZOSTER -022 demonstrated that the first 
primary  objective has been successfully  met, with 89.8% (95% CI of 84.3- 93.7) efficacy  
against HZ in subjects ‚â•70 YOA, and are therefore consistent with the results of 
ZOSTER -006. In addition, the co -primary  objective of a pre -specified pooled anal ysis of 
ZOSTER -006 and ZOSTER -022 demonstrated that HZ/su has a vaccine efficacy against 
HZ of 91.3% (with 95% CI  of 86.8 -94.5) and effectively  prevents PHN in subjects ‚â•70 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 32YOA (efficacy  of 88.8% with 95% CI  of 68.7 -97.1). No safety  concerns have been raised 
[Cunningham , 2016].
The immunogenicit y, reactogenicity, and safet y of HZ/su when co -administered with a 
23-valent pneumococcal poly saccharide conjugate vaccine ( Pneumovax 23 [trade name 
for Canada, Germ any and United States]/ Pneumo 23 [trade name for Estonia], Merck& 
Co., I nc) have been assessed in a phase III stud y in subjects ÔÇ≥ 50 YOA (ZOSTER- 035).
The immunogenicit y co-primary  objectives have been met.
Please refer to the current I nvestigator Brochure (IB) for information regarding the pre -
clinical and clinical studies of GSK Biologicals‚Äô study HZ/su vaccine.
1.2. Rationale for the study  and study  design
The objective of the current phase III study  is to assess immunogenicit y, reactogenicit y 
and safet y of GSK Biologicals‚Äô HZ vaccine when its first dose is co -administered with a 
pneumococcal poly saccharide conjugate vaccine ( Prevenar13 ) in adults aged ÔÇ≥50 YOA, 
as compared to the control group where the two HZ/su doses are administered subsequent 
to Prevenar13 .
The two parallel arms study  design was selected to allow an assessment of the 
immunogenicit y, reactogenicity and safety of HZ/su and Prevenar13 vaccines when they  
are co -administered and when administered separately in a staggered schedule 
(Prevenar13 followed b y HZ/su).
1.3. Benefit : Risk A ssessment
Please refer to the current IB for the summary  of potential risks and benefits of GSK 
Biologicals‚Äô study HZ vaccine (HZ/su).
Please refer to the Prescribing Information for information regarding the summary  
potent ial risks and benefits of Prevenar13.
The following section outlines the risk assessment and mitigation strategy  for this study  
protocol:204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 341.3.2. Benefit A ssessment
Benefits include:
ÔÇ∑Recei ving HZ/su during the study  may  reduce the risk of HZ occurrence and HZ -
related complications.
ÔÇ∑Receiving Prevenar13 during the study  may  prevent occurrence of pneumococcal 
pneumonia and invasive disease caused b y 13 Streptococcus pneumoniae strains (1, 
3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F).
ÔÇ∑Medical evaluations/assessments associated with study  procedures (e.g. physical 
examination).
1.3.3. Overall Benefit: Risk Conclusion
Considering the measures taken to minimize risk to subjects par ticipating in this study , 
the potential or recognized risks identified in association with the study HZ vaccine 
(HZ/su) and stud y procedures are justified by the potential benefits ( prevention of HZ 
and related complications) that may  be afforded to the su bjects receiving HZ/su .
Please refer to the approved product label/package insert for the summary  of potential 
risks and benefits of Prevenar13 .
2. OBJECTIVES
2.1. Co-Primary  objectives
ÔÇ∑To determine the vaccine response rate (VRR) to HZ/su (based on humoral immune
response) one month after the second vaccine dose , when the first dose of HZ/su is 
co-administered with Prevenar13 (Co-Ad group) .
Criterion to be used: 
The objective is met if the lower limit (LL) of the 95% CI of the VRR for anti -gE
antibody concentrations in the Co-Adgroup one month after the second vaccine dose 
is ‚â•60%.
If the above objective is met in the Co-Adgroup , then the following objective will be 
evaluated:
ÔÇ∑To demonstrate non -inferiority  of the humoral immune response to two doses of 
HZ/su at one month after the last vaccine dose, when the first dose of HZ/su is co -
administered with Prevenar13 (Co-Ad group) compared to when two doses of HZ/su 
are administered subsequent to Prevenar13 (Control Group).204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 35Criterion for non- inferiority: 
One month after the last vaccine dose in each study group, the upper limit (UL) of 
the 95% confidence interval (CI) for the anti- gE antibodies Geometric Mean 
Concentration (GMC) ratio between the Control group and the Co- Ad group is <1.5.
If the above non -inferiority  objective is met, then the following objective will be 
evaluated:
ÔÇ∑To demonstrate non -inferiority  of the humoral immune response to Prevenar13 at 
one month after the vaccine dose, when Prevenar13 is co-administered with the firs t 
HZ/su dose (Co -Ad group) compared to when Prevenar13 is administered separately  
from HZ/su (Control group), for the 13 serot ypes included in Prevenar13 analy zed 
sequentially .
Criterion for non- inferiority: 
One month after the Prevenar13 vaccine dose i n each study group, the UL of the 
95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer 
(GMT) ratio of the Control group over the Co- Ad group is <2.
For the co- primary  objectives, fixed sequence testing which allows for full alp ha 
propagation in pre -ordered hy potheses families will be used (see section 10.7.2 ).
Refer to Section 10.1 for the def inition of the primary  endpoints.
2.2. Secondary  obje ctive
ÔÇ∑To evaluate the safet y and reactogenicity  following administration of HZ/su and 
Prevenar13 vaccines, up to one month post last vaccination and during the whole 
follow -up period, in the Control group and the Co -Ad group.
Refer to Section 10.2 for the defin ition of the secondary  endpoint s.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 363. STUDY DESIGN OVERVIEW
Figure 1 Overview of Study  Design 
Vacc: vaccination; BS: blood sample; Pre -Vacc: pre -vaccination; FU: follow- up
Protocol waivers or exemptions are not allowed unless necessary  for the management of 
immediate safet y concerns. Therefore, adherence to the study design requirements, 
including those specified in the outline of study  procedures (Section 5.6), are essential 
and required for stud y conduct. 
ÔÇ∑Experimental design : Phase IIIB, open -label, randomized, controlled, multi- centric , 
and multi -country , with two parallel groups. 
ÔÇ∑Duration of the study : The intended duration of the study per subject is 
approximately  14 months for subjects from the Co -Ad group and approximately  
16months f or subjects from the Control group.
Epoch 001 : Primary starting at Visit Day  1 and ending with the phone contact at Month 
16.
ÔÇ∑Primary completion date (PCD) : Visit Month 5. 
Refer to glossary  of terms for the definition of PCD.
ÔÇ∑End of Study (EoS ): Last testing results released of samples collected at Visit 
Month 3 (Co- Ad group) or at Visit Month 5 (Control group). 
Refer to glossary  of terms for the definition of EoS.
204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 37ÔÇ∑Study groups :
Table 1 Study  groups and epochs foreseen in the study
Study groups Number of subjects AgeEpochs
Epoch 001
Co-Ad 456 ÔÇ≥50 years x
Control 456 ÔÇ≥50 years x
Table 2 Study  groups and treatment foreseen in the study
Treatment name Vaccine/Product name Study Groups
Co-Ad Control 
HZ/su VZV gE x x
AS01B x x
Prevenar13 Prevenar 13 x x
ÔÇ∑Control : active control .
ÔÇ∑Vaccination schedule(s):
Co-Ad Group: 
ÔÄ≠at Visit Day  1: first dose of HZ/su and one dose of Prevenar13 ,
ÔÄ≠at Visit Month 2: second dose of HZ/su. 
Control Group: 
ÔÄ≠at Visit Day  1: one dose of Prevenar13, 
ÔÄ≠at Visit Month 2: first dose of HZ/su,
ÔÄ≠at Visit Month 4: second dose of HZ/su.
ÔÇ∑Treatment allocation : Subjects to be randomized in a 1:1 ratio at Visit Day  1 to 
either Co- Ad or Control group. Subjects in each group will be stratified b y age with 
the following approximate distribution (not less than 25% in each age strata):
ÔÄ≠171 subjects in the 50- 59 YOA stratum, 
ÔÄ≠171 subjects in the 60- 69 YOA stratum, and
ÔÄ≠114 subjects in the ‚â• 70 YOA str atum.
ÔÇ∑Blinding :open -label. 
Table 3 Blinding of study  epochs
Study Epochs Blinding
Epoch 001 open204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 38ÔÇ∑Sampling schedule : Blood samples (approximately  8 mL) will be collected for each 
group, as described below.
For Co -Ad group: 
ÔÄ≠at Visit Day  1 to assess baseline antibody  concentrations/titers with respect to 
Prevenar13 and HZ/su vaccine antigens, prior to vaccination, 
ÔÄ≠at Visit Month 1 to assess humoral immune response with respect to Prevenar13
vaccine antigens, 1 month post -vaccination,
ÔÄ≠at Visit Month 3 to assess humoral immune response with respect to the HZ/su 
vaccine antigen, 1 month post-second vaccination dose.
For Control group :
ÔÄ≠at Visit Day  1 to assess baseline antibody  concentrations/titers with respect to 
Prevenar13 vaccine antigens, prior to vaccination, 
ÔÄ≠at Visit Month 1 to assess humoral immune response with respect to Prevenar13
vaccine antigens, at 1 month post -vaccination,
ÔÄ≠at Visit Month 2 to assess baseline antibod y concentrations/titers with respect to 
the HZ /su vaccine antigen, prior to first vaccination dose,
ÔÄ≠at Visit Month 5 to assess humoral immune response with respect to the HZ/su 
vaccine antigen, at 1 month post -second vaccination dose.
For both groups :
ÔÄ≠A urine specimen will be collected from all female subjects of childbearing
potential at Visit Day  1 and Visit Month 2 for Co -Ad group, and at Visit Day  1, 
Visit Month 2 and Visit Month 4 for the Control group. If a serum pregnancy  test 
instead of a urine pregnancy  test is required by  country , local or et hics committee 
regulations, a blood sample will be collected from women of childbearing
potential at these visits and will be used for the test as per local guidance.
Note: the result of the urine/serum pregnancy test must be obtained before 
vaccination .
ÔÇ∑Type of study : self-contained .
ÔÇ∑Data collection : Electronic Case Report Form ( eCRF ).
ÔÇ∑Safety monitoring : An internal GSK Safet y Review Team (SRT) part of the HZ/su
vaccine project will oversee the safet y of the study subjects on a regular basis. 
Serious Adverse Events (SAEs) and Adverse Events (AEs) including p IMDs will be 
reviewed b y the SRT at regular intervals together with data from other ongoing 
HZ/su vaccine s tudies. Any  potential safet y concern related to conduct of the study 
will be escalated to higher internal decision boards as per internal GSK process.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 394. STUDY COHORT
4.1. Number of subjects/centres
Target enrollment will be approximately  912 eligible subjects, to obtain 820 evaluable 
subjects (410 in each study  group). Detailed description of the criteria used in the 
estimation of sample size can be found in Section 10.3.
Within each study  group, subjects will be stratified by age at the time of recruitment (not 
less than 25% in each age strata) , as described in Table 4.
Table 4 Age Stratification
(Amended 30 January 2018)
Group Description Estimated number of subjects
Co-AdSubjects 50 to 59 YOA 171
Subjects 60 to 69 YOA 171
Subjects ÔÇ≥70 YOA 114
ControlSubjects 50 to 59 YOA 171
Subjects 60 to 69 YOA 171
Subjects ÔÇ≥70 YOA 114
YOA: years of age.
Overview of the recruitment plan
ÔÇ∑This study  is planned to be conducted at sites in multiple countries.
ÔÇ∑The recruitment rate will be monitored using a study -specific central Randomization 
System on Internet ( SBIR). 
ÔÇ∑The randomization algorithm will use a stratification procedure accounting for the 
three age strata (50 -59 YOA, 60 -69 YOA and ‚â•70 YOA).
4.2. Inclusion criteria for enrolment
Deviations from inc lusion criteria are not allowed because they  can potentially  jeopardize 
the scientific integrit y, regulatory  acceptability of the study  or subject safety . Therefore, 
adherence to the criteria as specified in the protocol is essential.
All subjects must sat isfy ALL the following criteria at study  entry :
ÔÇ∑Subjects who, in the opinion of the investigator, can and will comply  with the 
requirements of the protocol (e.g. completion of the diary  cards, return for follow -up 
visits).
ÔÇ∑Written informed consent obtai ned from the subject prior to performance of an y 
study  specific procedure.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 40ÔÇ∑A male or female, aged ÔÇ≥50 YOA at the time of the first vaccination with the study  
vaccine(s).
ÔÇ∑Female subjects of non -childbearing potential may  be enrolled in the study. Non -
childbearing potential is defined as pre -menarche, current bilateral tubal ligation or 
occlusion, hy sterectom y, bilateral ovariectomy or post -menopause.
Please refer to the glossary  of terms for the definition of menarche and menopause.
ÔÇ∑Female subjects of childbearing potential may  be enrolled in the study , if the subject: 
ÔÄ≠has practiced adequate contraception for 30 day s prior to vaccination, and 
ÔÄ≠has a negative pregnancy test on the day  of vaccination, and 
ÔÄ≠has agreed to continue adequate contraception during the entire treatment period 
and for 2 months after completion of the vaccination series.
Please refer to the glossary  of terms for the definition of adequate contraception.
4.3. Exclusion criteria for enro lment
Deviations from exclusion criteria are not allowed because they  can potentially  
jeopardize the scientific integrit y, regulatory  acceptability of the study  or subject safet y. 
Therefore, adherence to the criteria as specified in the protocol is essenti al.
The following criteria should be checked at the time of study  entry . If ANY exclusion 
criterion applies, the subject must not be included in the study :
ÔÇ∑Use of an y investigational or non -registered product (drug or vaccine) other than the 
study  vaccines during the period starting 30 day s before the first dose of study  
vaccines (Day  -30 to Day 1), or planned use during the study  period.
ÔÇ∑Any medical condition that in the judgment of the investigator would make 
intramuscular (IM) injection unsafe.
ÔÇ∑Use or anticipated use of immunosuppressants or other immune- modify ing drugs 
during the period starting six months prior to study  start and during the whole study  
period. This includes chronic administration of corticosteroids (>14 consecutive day s 
of prednisone at a dose of ‚â•20 mg/day  [or equivalent]), long -acting immune 
modify ing agents (e.g., infliximab) or immunosuppressive/cy totoxic therapy  (e.g., 
medications used during cancer chemotherapy, organ transplantation or to treat 
autoimmune disorders). Inhaled, topical and intra -articular corticosteroids are 
allowed.
ÔÇ∑Administration or planned administration of a vaccine not foreseen b y the study  
protocol in the period starting 30 day s before the first dose and ending 30 day s after 
the last dose of study  vaccin e administration. This includes an y type of vaccine such 
as (but not limited to) live, inactivated and subunit vaccines (e.g., inactivated and 
subunit influenza vaccines).204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 41ÔÇ∑Concurrentl y participating in another clinical study, at an y time during the study
period, in which the subject has been or will be exposed to an investigational or a 
non-investigational vaccine/product (pharmaceutical product or device).
ÔÇ∑Previous and/or planned administration of an HZ or VZV vaccine (including an 
investigational or n on-registered vaccine) other than the study  vaccine during the 
study  period.
ÔÇ∑History  of HZ.
ÔÇ∑History  of documented pneumococcal infection within 5 previous y ears.
ÔÇ∑Prior receipt of any pneumococcal vaccine or planned use during the stud y period, 
other than the stud y vaccines.
ÔÇ∑Any confirmed or suspected immunosuppressive or immunodeficient condition 
resulting from disease (e.g., malignancy , human immunodeficiency  virus [HIV] 
infection) or immunosuppressive/cy totoxic therapy  (e.g., medications used during 
cancer chemotherap y, organ transplantation or to treat autoimmune disorders).
ÔÇ∑History of any  reaction or hy persensitivity  likel y to be exacerbated b y any 
component of the vaccines.
ÔÇ∑Acute disease and/or fever at the time of enrollment.
ÔÄ≠Fever is defined as temperature ÔÇ≥38.0¬∞C/100.4¬∞F. The preferred location for 
measuring temperature in this study  will be the oral cavity .
ÔÄ≠Subjects with a minor illness (such as mild diarrhea, mild upper respiratory 
infection) without fever may , be enrolled at the discretion of the investigator. 
ÔÇ∑Administration of immunoglobulins and/or an y blood products during the period 
starting 3 months before the first dose of stud y vaccine or planned administration 
during the stud y period.
ÔÇ∑Pregnant or lactating female.
ÔÇ∑Female planning to become pregnant or planning to discontinue contraceptive 
precautions before 2 months after the last dose of study  vaccine.
ÔÇ∑Any person with cerebrospinal fluid (CSF) leaks, cochlear implants, chronic renal 
failure, nephrotic s yndrome and functional or anatomic asplenia.
ÔÇ∑Any medical condition that in the judgment of the investiga tor would prevent the 
subject from participating in the stud y.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 425. CONDUCT OF THE STUDY
5.1. Regulatory  and ethical considerations, including the 
informed consent process
The study  will be conducted in accordance with all applicable regulatory  requirements.
The study  will be conducted in accordance with the I CH Guideline for GCP , all 
applicable subject privacy requirements and the guiding principles of the Declaration of 
Helsinki. 
GSK will obtain favourable opinion/approval to conduct the study  from the appr opriate 
regulatory  agency , in accordance with applicable regulatory  requirements, prior to a site 
initiating the study  in that country .
Conduct of the study  includes, but is not limited to, the following:
ÔÇ∑Institutional Review Board (IRB)/Independent Ethics Committee (I EC) review and 
favourable opinion/approval of study  protocol and any  subsequent amendments.
ÔÇ∑Subject informed consent .
ÔÇ∑Investigator reporting requirements as stated in the protocol.
GSK will provide full details of the above procedures to the i nvestigator, either verbally , 
in writing, or both.
Freely  given and written or witnessed/ thumb printed informed consent must be obtained 
from each subject prior to participation in the study. 
GSK Biologicals will prepare a model Informed Consent Form (IC F) which will embody  
the ICH GCP and GSK Biologicals required elements. While it is strongly  recommended 
that this model I CF is to be followed as closely  as possible, the informed consent 
requirements given in this document are not intended to pre- empt an ylocal regulations 
which require additional information to be disclosed for informed consent to be legall y 
effective. Clinical judgement, local regulations and requirements should guide the final 
structure and content of the local version of the ICF. 
The investigator has the final responsibility  for the final presentation of the ICF, 
respecting the mandatory requirements of local regulations. The ICF generated b y the 
investigator with the assistance of the sponsor‚Äôs representative must be acceptable to 
GSK Biologicals and be approved (along with the protocol, and an y other necessary  
documentation) b y the IRB/IEC.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 435.2. Subject identification and randomi zation
5.2.1. Subject identification
Subject identification numbers will be assigned sequentially to the subjects who h ave 
consented to participate in the study, according to the range of subject identification 
numbers allocated to each study  centre.
5.2.2. Randomi zation of treatment
The treatment allocation will be performed using SBI R. The treatment numbers will be 
allocated b ydose. The allocation ratio will be 1:1 between each stud y group.
Randomi zation of supplies 5.2.2.1.
The randomiz ation of supplies within blocks will be performed at GSK Biologicals, using 
MATerial EXcellence ( MATEX), a program developed for use in Statistical Anal ysis 
System ( SAS¬Æ) (Cary , NC, USA) by  GSK Biologicals. Entire blocks will be shipped to 
the study  centres /warehouse(s).
To allow GSK Biologicals to take advantage of greater rates of recruitment than 
anticipated at individual centres in this multi -centre study  and to thus reduce the overall 
study  recruitment period, an over -randomi zation of supplies will be prepared. 
Treatment allocation to the subject 5.2.2.2.
The treatment numbers will be allocated b y dose.
5.2.2.2.1. Study group and treatment number allocation
The target will be to enrol approximately  912 eligible subjects who will be randomly  
assigned to two stud y groups in a 1:1 ratio (approximately 456 in each study group).
The enrolment will be performed to ensure distribution of the population across the th ree 
age strata (50 -59 YOA, 60 -69 YOA and ÔÇ≥ 70 YOA). Therefore the expected distribution 
of subjects is as shown in Table 5 .
Age will be calculated as the number of years between the date of birth and the date of 
first vaccination. To ensure that the collection of date of birth will not jeopardise the 
privacy  of Personally  Identifiable Information (PII), only  a partial date of birth *
(MMYYYY) will be collected. Therefore, the 15th of the month will be used to replace 
the missing date.
In case the month is missing, the date will be replaced b y the June 30th of the year.
* In Germany, as per local regulations, only the year of birth will be collected.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 44Table 5 Number of subjects required for enrolment
Age Stratum Vaccine N
50-59 YOAHZ/su342Prevenar13
60-69 YOAHZ/su342Prevenar13
‚â• 70 YOAHZ/su228Prevenar13
N = number of subjects to be enrolled
Allocation of the subject to a study  group at the investigator site will be performed using 
SBIR.Within each age strata (50 -59 YOA, 60 -69 YOA and ÔÇ≥70 YOA), the 
randomi zation algorithm will use a minimisation procedure accounting for centre. 
After obtaining the signed an d dated ICF from the subject and having checked the 
eligibility  of the subject, the study  staff in charge of the vaccine administration will 
access SBIR. Upon providing the age (50 -59 YOA, 60- 69 YOA and ÔÇ≥70 YOA) at the 
time of enrolment in the study  and t he subject identification number, the randomization 
system will determine the study  group and will provide the treatment number(s) to be 
used for the first dose.
The number of each administered treatment must be recorded in the eCRF on the Vaccine 
Administration screen.
When SBI R is not available, please refer to the SBIR user guide or the Study  Procedures 
Manual (SPM) for specific instructions.
5.2.2.2.2. Treatment number allocation for subsequent doses 
For each dose subsequent to the first d ose, the study staff in charge of the vaccine
administration will access SBI R, provide the subject identification number, and the 
system will provide a treatment number consistent with the allocated study group.
The number of each administered treatment must be recorded in the eCRF on the Vaccine 
Administration screen.
5.3. Method of blinding 
This study  is an open- label study .
The laboratory  in charge of the laboratory  testing will be blinded to the treatment, and 
codes will be used to link the subject and stud y (without any link to the treatment 
attributed to the subject) to each sample.
5.4. General study  aspects
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the accompany ing SPM. The SPM provides the investigator and the site 
personnel with administrative and detailed technical information that does not impact the 
safet y of the subjects.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 455.5. Suspected HZ cases
Suspected HZ is defined as a new rash characteristic of HZ (i.e., unilateral, dermatomal 
and accompanied b y pain broadly  defined to include allody nia, pruritus or other 
sensations). A diagnosis of suspected HZ will be based upon investigator judgment. 
Complications of HZ include, but are not limited to, PHN, HZ vasculitis, disseminated 
disease, ophthalmic disease , neurologic disease, and visceral disease. 
The occurrence of HZ is an intercurrent medical condition (see Section 6.8) which should 
be reported u ntil study  end. All other intercurrent medical conditions should be reported 
until Month 3 for subjects from the Co-Ad group and Month 5 for subjects from the 
Control group. 
The standard reporting period as specified in Section 8.4.1 for Adverse Event 
(AE)/Serious Adverse Event (SAE) should be used for HZ complications.
At Visit Day  1, all subjects will be informed of the signs and s ymptoms of ty pical HZ . 
5.6. Outline of study  procedures
The lists of study  procedures are presented in Table 6and Table 7 for Co- Ad and Control 
groups, respectively .
Table 6 List of study  procedures for Co -Ad Group
Epoch Epoch 001
Type of contact Visit Visit Visit Visit Phone 
contact 
Timepoint (s) Day 1 Month 1 Month 2 Month 3 Month 
14
Sampling timepoint(s) Pre-
vaccPrevenar13
Post -vacc HZ/su Post -
vacc 2 
Informed consent ‚óè
Inclusion/exclusion criteria ‚óè
Collect and record demographic data ‚óè
General Medical history ‚óè
Vaccination history ‚óè
General physical examination (history directed) O
Pregnancy tes t1 ‚óè ‚óè
Check contraindications and warnings and precautions ‚óè ‚óè
Pre-vaccination body temperature2 ‚óè ‚óè
Randomization O
Study group and treatment number allocation O
Recording of administered treatment number ‚óè ‚óè
Blood sampling for antibody determination (~8 m L) in all 
subjects‚óè ‚óè ‚óè
HZ/su administration ‚óè ‚óè3
Prevenar13 vaccine administration ‚óè
Post-vaccination observation (30 minutes minimum) O O
Training on self -reporting by subjects4 O O O O
Training on completion of diary cards O O204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 46Epoch Epoch 001
Type of contact Visit Visit Visit Visit Phone 
contact 
Timepoint (s) Day 1 Month 1 Month 2 Month 3 Month 
14
Sampling timepoint(s) Pre-
vaccPrevenar13
Post -vacc HZ/su Post -
vacc 2 
Distribution of diary cards for solicited AEs, unsolicited AEs 
and concomitant medication/vaccination to subjectsO O
Daily recording of solicited AEs by subjects (Days 1 -7 after 
each vaccination)5O O
Daily recording of unsolicited AEs and concomitant 
medication/vaccination by subjects (Days 1 -30 after each 
vaccination)O O
Return of diary cards for solicited AEs, unsolicited AEs and 
concomitant medication/vaccinationO O
Transcription of diary cards for solicited AEs, unsolicited 
AEs and concomitant medication/vaccination by study 
staff/investigator‚óè ‚óè
Recording of serious adverse event6 ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of pIMDs ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of pregnancy ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of intercurrent medical conditions other than HZ7 ‚óè ‚óè ‚óè ‚óè
Recording of HZ (intercurrent medical condition)8 ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of concomitant medication/vaccination9 ‚óè ‚óè ‚óè ‚óè ‚óè
Study conclusion ‚óè
Note: The double -line border following Month 3 indicates the analyses which will be performed on all data (i.e. data that 
are as clean as possible) obtained up to Month 3 for Co -Ad group.
Pre-vacc: pre -vaccination, post -vac: post- vaccination. AE: adverse event; HZ: Herpes Zoster.
‚óè is used to indicate a study procedure that requires documentation in the individual eCRF.
‚óã is used to indicate a study procedure that does not require documentation in the individual eCRF .
1. For women of childbearing potential. If a serum pregnancy test instead of a urine pregnancy test is required by 
country, local or ethics committee regulations, a blood sample will be collected from women of childbearing potential .
2. Pre -vaccination temperatures should always be recorde d orally at study sites. In rare situations when there is no 
other alternative, the temperature may be recorded by other route. If the temperature is taken by another route 
(axillary, rectal or tympanic), the route should be documented.
3. Any subject with a suspected HZ episode anytime following the first HZ/su dose should not receive the second HZ/su 
dose or any subject with an event of HZ between Visit Day 1 and any dose of HZ/su vaccine should not receive the 
upcoming dose(s) of the HZ/su vaccine .
4. Subjects will be instructed to contact their study site immediately if they manifest any symptoms they perceive as 
serious and, in case of pregnancy for women of childbearing potential.
5. The preferred route for the daily recording of temperature is oral. When there is no other alternative, the temperature 
may be recorded by other route. If the temperature is taken by another route (axillary, rectal or tympanic), the route 
should be documented.
6. All serious adverse events (SAEs) related to study participation or GSK concomitant medication/vaccine are to be 
recorded from the time the subject consents to participate in the study. All other SAEs are to be reported after 
administration of the first dose of vaccine.
7.According to Section 6.8
8.At Visit Day 1, all subjects will be informed of the signs and symptoms of typical HZ.
9. According to Section 6.7.1204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 47Table 7 List of study  procedures for Control Group
Epoch Epoch 001
Type of contact Visit Visit Visit Visit Visit Phone 
contact 
Timepoint (s) Day 1 Month 1 Month 2 Month 4 Month 5 Month 
16
Sampling timepoint(s) Pre-vacc Prevenar13
Post -vaccPre-vacc HZ/su 
Post -
vacc 2
Informed consent ‚óè
Inclusion/exclusion criteria ‚óè
Collect and record demographic data ‚óè
General medical history ‚óè
Vaccination history ‚óè
General physical examination (history directed) O
Pregnancy test 1 ‚óè ‚óè ‚óè
Check contraindications and warnings and precautions ‚óè ‚óè ‚óè
Pre-vaccination body temperature2 ‚óè ‚óè ‚óè
Randomization O
Study group and treatment number allocation O
Recording of administered treatment number ‚óè ‚óè ‚óè
Blood sampling for antibody determination (~8 mL) in all 
subjects‚óè ‚óè ‚óè ‚óè
HZ/su administration ‚óè3 ‚óè3
Prevenar13 vaccine administration ‚óè
Post-vaccination observation (30 minutes minimum ) O O O
Training on self -reporting by subjects4 O O O O O
Training on completion of diary cards O O O
Distribution of diary cards for solicited AEs, unsolicited 
AEs and concomitant medication/vaccination to subjectsO O O
Daily recording of solicited AEs by subjects (Days 1 -7 
after each vaccination)5O O O
Daily recording of unsolicited AEs and concomitant 
medication/vaccination by subjects (Days 1 -30 after 
each vaccination)O O O
Return of diary cards for solicited AEs, unsolicited AEs 
and concomitant medication/vaccinationO O O
Transcription of diary cards for solicited AEs, unsolicited 
AEs and concomitant medication/vaccination by study 
staff/investigator‚óè ‚óè ‚óè
Recording of serious adverse event6 ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of pIMDs ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of pregnancy ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of intercurrent medical conditions other than 
HZ7 ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of HZ (intercurrent medical condition)8 ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of concomitant medication/vaccination9 ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè
Study conclusion ‚óè
Note: The double -line border following Month 5 indicates the analyses which will be performed on all data (i.e. data that 
are as clean as possible) obtained up to Month 5 for Control group.
Pre-vacc: pre -vaccination, post -vac: post - vaccination; AE: adverse eve nt; HZ: Herpes Zoster.
‚óè is used to indicate a study procedure that requires documentation in the individual eCRF .
‚óã is used to indicate a study procedure that does not require documentation in the individual eCRF .
1. For women of childbearing potential. If a serum pregnancy test instead of a urine pregnancy test is required by 
country, local or ethics committee regulations, a blood sample will be collected from women of childbearing potential .204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 482. Pre -vaccination temperatures should always be recorde d orally at study sites. In rare situations when there is no 
other alternative, the temperature may be recorded by other route. If the temperature is taken by another route 
(axillary, rectal or tympanic), the route should be documented.
3.Any subject with a suspected HZ episode anytime following the first HZ/su dose should not receive the second HZ/su 
dose or any subject with an event of HZ between Visit Day 1 and any dose of HZ/su vaccine should not receive the 
upcoming dose(s) of the HZ/su vaccine .
4. Subjects will be instructed to contact their study site immediately if they manifest any symptoms they perceive as 
serious and, in case of pregnancy for women of childbearing potential.
5. The preferred route for the daily recording of temperature is oral. When there is no other alternative, the temperature 
may be recorded by other route. If the temperature is taken by another route (axillary, rectal or tympanic), the route 
should be documented.
6. All serious adverse events (SAEs) related to study participation or GSK concomitant medication/vaccine are to be 
recorded from the time the subject consents to participate in the study. All other SAEs are to be reported after 
administration of the first dose of vaccine.
7. According to Section 6.8.
8.At Visit Day 1, all subjects will be informed of the signs and symptoms of typical HZ.
9. According to Section 6.7.1
Whenever possible the investigator should arrange study  visits within the intervals 
provided in Table 8 and Table 9 for Co- Ad and Control groups, respectively .
Table 8 Intervals between study visits/contact for Co -Ad group
Interval Optimal length of interval1 Allowed interval
Visit Day 1 ÔÇÆVisit Month 1 1month 30-42days1
Visit Day 1 ÔÇÆVisit Month 2 2months 49-83days1
Visit Month 2 ÔÇÆVisit Month 3 1month 30-48days1
Visit Month 2 ÔÇÆPhone contact Month 14 12months 335-395days
1Subjects may not be eligible for inclusion in the :Per-protocol cohort (PPC) for analysis of immunogenicity if they make 
the study visit outside this interval.
Table 9 Intervals between study visits/contact for Control group
Interval Optimal length of interval1 Allowed interval
Visit Day 1 ÔÇÆVisit Month 1 1month 30-42days1
Visit Day 1 ÔÇÆVisit Month 2 2 months 60 -83 days 1
Visit Month 2 ÔÇÆ Visit Month 4 2months 49-83days1
Visit Month 4 ÔÇÆVisit Month 5 1month 30-48days1
Visit Month 4 ÔÇÆPhone contact Month 16 12months 335-395days
1Subjects may not be eligible for inclusion in the PPC for analysis of immunogenicity if they make the study visit outside 
this interval.
5.7. Detailed description of study  procedures
5.7.1. Informed consent
The signed/witnessed/thumb printed informed consent of the subject must be obta ined 
before stud y participation . Refer to Section 5.1for the requirements on how to obtain 
informed consent .204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 495.7.2. Check inc lusion and exclusion criteria
Check all inclusion and exclusion criteria as described in Sections 4.2and 4.3before 
enrolment. 
5.7.3. Collect demographic data
Record demographic data such as date of birth *, sex, race and ethnicity  in the subject‚Äôs 
eCRF.
* In German y, as per local regulations, only  the year of birth will be collected.
5.7.4. General medical history
Obtain the subject‚Äôs medical history  by interview and/or review of the subject‚Äôs medical 
records and record an y pre-existing conditions or signs and/or s ymptoms present in a 
subject prior to the firststudy  vaccination in the eCRF.
5.7.5. History  directed physical examination
Perform a history  directed phy sical examination. If the investigator determines that the 
subject‚Äôs health on the day of vaccination temporarily  precludes vaccination, the visit will
be rescheduled.
Treatment of any abnormality observed during this examination has to be performed 
according to local medical practice outside this study  or by referral to an ap propriate 
health care provider.
5.7.6. Pregnancy  test
Female subjects of childbearing potential are to have a urine /blood pregnancy test prior to 
any study  vaccine administration. Generally , a urine pregnancy  test is sufficient. A serum 
pregnancy test instead of a urine pregnancy  test should only  be considered if required b y 
country , local or ethics committee regulations. The results of the applicable test will be 
recorded in the eCRF. The study  vaccine (s) may only  be administered if the pregnancy  
test is negative. 
Note: P regnancy  test must be performed even if the subject is menstruating at the time of 
the study  visit.
5.7.7. Check contraindications, warnings and precautions to 
vaccination 
Contraindications, warnings and precautions to vaccination must be checked at the 
beginning of each vaccination visit. Refer to Sections 6.5 and 6.6for more details.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 505.7.8. Assess pre -vaccination body temperature
The body  temperature of each subjects needs to be measured prior to an y study vaccine (s)
administration. The preferred location for measuring temperature in this study  will be the 
oral cavit y.If the subject has fever [fever is defined as tempe rature ÔÇ≥ 38.0¬∞C/100.4¬∞F 
regardless the location of measurement] on the day  of vaccination, the vaccination visit 
will be rescheduled within the allowed interval for this visit (see Table 8 and Table 9 ).
In rare situations when there is no other alternative, the temperature may be recorded b y 
other ro ute. If the temperature is taken b y another route (axillary , rectal or ty mpanic), the 
route should be documented.
5.7.9. Study group and treatment number allocation
Study  group and treatment number allocation will be performed as described in Section 
5.2.2. The number of each administered treatment must be recorded in the eCRF .
5.7.10. Sampling
Refer to the Investigator Lab Manual for detailed instructi ons for the collection, handling 
and processing of the samples.
Blood sampling for immune response assessments 5.7.10.1.
Blood samples will be taken during certain study  visits as specified in Section 5.6List of 
Study  Procedures.
ÔÇ∑A volume of at least approximately  8mL of whole blood (to provide at least 2.8 mL  
of serum) should be drawn from all subjects for each anal ysis of humoral immune 
response at each pre -defined timepoint. After centrifugation, serum samples should 
be kept at ‚Äì 20¬∞C/ ‚Äì4¬∞F or below until shipment. Refer to the Investigator Lab 
Manual for more details on sample storage conditions.
5.7.11. Study Vaccine(s) administration
ÔÇ∑After completing all prerequisite procedures prior to vaccination, the dose(s) of 
vaccine(s) will be administered IM in the deltoid(s) of the arms according to the 
administration schedule (refer to Section 6.3 for detaile d description of the 
vaccine(s) administration procedure). If the investigator or delegate determines that 
the subject‚Äôs health on the day  of administration t emporarily  precludes vaccine(s)
administration, the visit will be rescheduled within the allowed interval for this visit 
(refer to Table 8 and Table 9).
ÔÇ∑The subjects will be observed closel y for at least 30minutes following the 
administration of the vaccine(s) , with appropriate medical treatment readil y available 
in ca se of anaph ylaxis.
ÔÇ∑Any subjects with an event of HZ between Visit Day 1and an y dose of HZ/su 
vaccine should not receive the upcoming dose(s) of the HZ/su vaccine.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 515.7.12. Check and record concomitant medication/vaccination and 
intercurrent medical conditions 
Concomitant medication/vaccination must be checked and recorded in the eCRF as 
described in Section 6.7.
Intercurrent medical conditions must be checked and recorded in the eCRF as described 
in Section 6.8.
5.7.13. Recording of A Es, SA Es, pregnancies and pIMDs
ÔÇ∑Refer to Section 8.3for procedures for the investigator to record A Es, SAEs, 
pregnancies and pIMDs . Refer to Section 8.4for guidelines andhow to report SAE, 
pregnancy  and pIMD reports to GSK Biologicals.
ÔÇ∑The subjects will be instructed to contact the inves tigator immediatel y should they
mani fest an y signs or s ymptoms they  perceive as serious. 
ÔÇ∑At each vaccination visit, diary  cards will be provided to the subject . The subject will 
be instructed to measure and record the oral body  temperature, and an y solicited 
local/general AEs (i.e. on the d ay of vaccination and during the next 6 day s) or any  
unsolicited AEs (i.e. on the day of vaccination and during the next 29daysoccurring
after vaccination. The subject will be instructed to return the completed diary card to 
the investigator at the next study  visit.
ÔÇ∑Collect and verify  completed diary  cards during discussion with the subject (at Visit 
Month 1 and Visit Month 3 in Co-Adgroup and at Visit Month 1, Visit Month 4 and 
Visit Month 5 in Control group).
ÔÇ∑Any unreturned diary  cards will be sought from the subject through telephone call(s) 
or an y other convenient method . 
ÔÇ∑The investigator will transcribe the collected information into the eCRF in English.
5.7.14. Study conclusion
The investigator will:
ÔÇ∑collect and record SAEs, pI MDs, any  pregnancy  cases, HZ occurences and 
concomitant medication/ vaccination taken,
ÔÇ∑review data collected to ensure accuracy  and completeness ,
ÔÇ∑complete the Study  Conclusion screen in the eCRF .204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 525.8. Biological sample handling and analy sis
Please refer to the Investigator Lab Manual for details on biospecimen management 
(handling, storage and shipment).
Samples will not be labelled with information that directly  identifies the subject but will 
be coded with the identification number for the subject (subject number).
ÔÇ∑Collected samples will be used for protocol mandated research and purposes related 
to the improvement, development and quality  assurance of the laboratory  tests 
described in this protocol. This may include the management of the quality  of these 
tests, the maintenance or improvement of these tests, the development of new test 
methods, as well as making sure that new tests are comparable to previous methods 
and work reliably .
ÔÇ∑It is also possible that future findings may  make it desirable to use the samples 
acquired in this stu dy for future research, not described in this protocol. Therefore, 
all subjects in countries where this is allowed will be asked to give a specific consent
to allow GSK or a contracted partner to use the samples for future research. Future 
research will be subject to the laws and regulations in the respective countries and 
will only  be performed once an independent Ethics Committee or Review Board has 
approved this research.
Information on further investigations and their rationale can be obtained from GSK 
Biologicals. 
Any sample testing will be done in line with the co nsent of the individual subject.
Refer also to the Investigator Agreement , where it is noted that the investigator cannot 
perform an y other biological assay s except those described in the protocol or its 
amendment(s). 
If additional testing is performed, th e marker priority  ranking given in Section 5.8.4 may 
be changed.
Collected samples will be stored for a maximum of 20 y ears (counting from when the last 
subject performed the last study  visit), unless local rules, regulations or guidelines require 
different timeframes or different procedures, which will then be in line with the subject 
consent. These extra requirements need to be communicated formall yto and discussed 
and agreed with GSK Biologicals.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 535.8.1. Use of specified study materials
When materials are provided by  GSK Biologicals, it is MANDATORY that all clinical 
samples (including serum samples) be collected and stored exclusively  using those 
material s in the appropriate manner. The use of other materials could result in the 
exclu sion of the subject from the per -protocol analy sis (See Section 10.4 for the 
definition of cohorts to be anal ysed). The investigator must ensure that his/her personnel 
and the laboratory (ies) under his/her supervision comply  with this requirement. However, 
when GSK Biologicals does not provide material for collecting and storing clinical 
samples, appropriate materials from the investigator‚Äôs site must be used. Refer to the 
Investigator Lab Manual .
5.8.2. Biological samples
The different biological samples collected in the study , the quantity  needed, the unit and 
the time points are described in Table 10 .
Table 10 Biological samples
Sample type Quantity Unit Timepoint Co -Ad group Timepoint Control group
Whole blood Approximately 8 mL Visit Day 1 
Visit Month 1
Visit Month 3 Visit Day 1
Visit Month 1 
Visit Month 2 
Visit Month 5 
5.8.3. Laboratory  assay s
Please refer to APPENDIX Afor a detailed description of the assay s performed in the 
study . Please refer to APPENDIX Bfor the address of the clinical laboratories used for 
sample anal ysis.
Serological assay s for the determination of anti -gEantibodies will be performed by  
enzy me-linked immunosorbent assay  (ELISA) at a GSK Biologicals‚Äô laboratory . 
Serological assay s for the determination of pneumococcal serot ype antibodies will be 
performed b y multiplex opsonophagocy tosis assay  (MOPA) at a la boratory  designated by  
GSK Biologicals using standardized and validated procedures (refer to Table 11).
(Amended 30January 2018)204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 54Table 11 Humoral Immunity  (Antibody  determination)
System Component Method Unit Cut-off Laboratory
Serum Varicella Zoster Virus Glycoprotein E Ab IgG ELISA mlU/mL 97 GSK Biologicals*
SerumStreptococcus pneumoniae Serotype 01/37 
Brugmann Hospital Ab
MOPA 1/dilution14
University of 
Alabama at 
Birmingham**Streptococcus pneumoniae Serotype 03/1 
Statens Serum Institut Ab10
Streptococcus pneumoniae Serotype 04/2656 
Brugmann Hospital Ab41
Streptococcus pneumoniae Serotype 05 
Ambrose -Statens Serum Institut Ab11
Streptococcus pneumoniae Serotype 06A 
Centers for Disease Control Ab15
Streptococcus pneumoniae Serotype 
06B/DS2212/94 Centers for Disease Control Ab29
Streptococcus pneumoniae Serotype 07F/46 
Brugmann Hospital Ab28
Streptococcus pneumoniae Serotype 09V/112 
161/95 Statens Serum Institut Ab14
Streptococcus pneumoniae Serotype 14/58 
Brugmann Hospital Ab14
Streptococcus pneumoniae Serotype 
18C/4593/40 Statens Serum Institut Ab26
Streptococcus pneumoniae Serotype 19A/DB18 
Kansanterveyslaitos Folkhalsoinstitutet Ab13
Streptococcus pneumoniae Serotype 19F/2737 
Brugmann Hospital Ab15
Streptococcus pneumoniae Serotype 23F Mac -
Statens Serum Institut Ab22
2GSK Biologicals laboratory refers to the Clinical Laboratory Sciences (CLS) in Rixensart, Belgium; Wavre, Belgium.
**Pathology Department of Professor, Moon H. Nahm , M.D, WHO Pneumococcal Serology Reference Laboratory, The 
University of Alabama at Birmingham, Bevill Building, Room 614 (BBRB 614), 845 19th Street South, Birmingham 
AL, 35294
MOPA: multiplex opsonophagocytosis assay; ELISA: enzyme -linked immunosorbent a ssay; Ab: antibody; IgG: 
immunoglobulin G; S pneumoniae: Streptococcus pneumoniae.
Additional exploratory  testing on the vaccine and/or on the disease under study  may  be 
performed within the framework of the stud y if deemed necessary  for accurate 
interpret ation of the data or should such assay (s) become available at GSK. These assay s 
may not be represented in the objectives/endpoints of the study  protocol.
The GSK Biologicals‚Äô / contract research organizations‚Äô (CRO) clinical laboratories 
have established a Quality  System supported b y procedures. The activities of GSK 
Biologicals‚Äô / CROs‚Äô clinical laboratories are audited regularly  for qualit y assessment by 
an internal (sponsor -dependent) but laboratory -independent Quality  Department. Clinical 
laboratories contracted by GSK also conform to Good Laboratory Practice guidelines 
and operat ein compliance with regulatory standards.
(Amended 30January 2018)204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 555.8.4. Biological samples evaluation
Immunological read -outs 5.8.4.1.
The plan for immunogenicity  testing on samples obtain ed is shown in Table 12 and Table 
13for Co -Adand Control groups, respectivel y.
Table 12 Immunological read -outs for Co -Ad group
Blood sampling timepoint
No. subjects ComponentType of contact and timepoint Sampling timepoint
Visit Day 11Prevenar13 pre-vaccination 456S pneumoniae 01 Ab
S pneumoniae 03 Ab
S pneumoniae 04 Ab
S pneumoniae 05 Ab
S pneumoniae 06A Ab
S pneumoniae 06B Ab
S pneumoniae 07F Ab
S pneumoniae 09V Ab
S pneumoniae 14 Ab
S pneumoniae 18C Ab
S pneumoniae 19A Ab
S pneumoniae 19F Ab
S pneumoniae 23F Ab
HZ/su pre-vaccination 456 VZV Glycoprotein E Ab IgG
Visit Month 1Prevenar13 post-
vaccination456S pneumoniae 01 Ab
S pneumoniae 03 Ab
S pneumoniae 04 Ab
S pneumoniae 05 Ab
Spneumoniae 06A Ab
S pneumoniae 06B Ab
S pneumoniae 07F Ab
S pneumoniae 09V Ab
S pneumoniae 14 Ab
S pneumoniae 18C Ab
S pneumoniae 19A Ab
S pneumoniae 19F Ab
S pneumoniae 23F Ab
Visit Month 3 HZ/su post-vaccination 456 VZV Glycoprotein E Ab IgG
Ab: antibody; IgG: immunoglobulin G; S pneumoniae: Streptococcus pneumoniae; VZV: Varicella Zoster Virus .
1In case of inadequate samples from Visit Day 1, anti -gEtesting (ELISA) will be prioritized over testing for 
pneumococcal serotype antibodies (MOPA). 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 56Table 13 Immunological read -outs for Control group
Blood sampling timepoint
No. subjects Component Type of contact and 
timepointSampling timepoint
Visit Day 1Prevenar13
pre-vaccination456S pneumoniae 01 Ab
S pneumoniae 03 Ab
S pneumoniae 04 Ab
S pneumoniae 05 Ab
S pneumoniae 06A Ab
S pneumoniae 06B Ab
S pneumoniae 07F Ab
S pneumoniae 09V Ab
S pneumoniae 14 Ab
S pneumoniae 18C Ab
S pneumoniae 19A Ab
S pneumoniae 19F Ab
S pneumoniae 23F Ab
Visit Month 1Prevenar13
post- vaccination456S pneumoniae 01 Ab
S pneumoniae 03 Ab
S pneumoniae 04 Ab
S pneumoniae 05 Ab
S pneumoniae 06A Ab
S pneumoniae 06B Ab
S pneumoniae 07F Ab
S pneumoniae 09V Ab
S pneumoniae 14 Ab
S pneumoniae 18C Ab
S pneumoniae 19A Ab
S pneumoniae 19F Ab
S pneumoniae 23F Ab
Visit Month 2 HZ/su pre-vacc 456 VZV Glycoprotein E Ab IgG
Visit Month 5 HZ/su post-vacc 456 VZV Glycoprotein E Ab IgG
Ab: antibody; IgG: immunoglobulin G; S pneumoniae: Streptococcus pneumoniae; VZV:Varicella Zoster Virus
5.8.5. Immunological correlates of protection
No generally  acce pted immunological correlate of protection against HZ has been 
demonstrated so far for the gE antigen used in the HZ/su study vaccine .
No correlate of protection for pneumococcal conjugate vaccines for use in adults has 
been established.
The investigator is encouraged to share the immunological assay  results for non-
responders with the study  subjects.
For the subjects identified as non- responders, it remains the responsibility  of the 
investigator in charge of the subject‚Äôs clinical management to determine the medical need 
for re -vaccination and to re -vaccinate the subjects as per local/regional practices.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 576. STUDY VA CCINE SAND ADM INISTRA TION
6.1. Description of study  vaccine s
The study vaccine to be used has been developed and manufactured by  GSK Biologicals. 
The Prevenar13 vaccine is marketed by  Pfizer Inc..
The Quality  Control Standards and Requirements for the study vaccine are described in 
separate Qualit y Assurance documents (e.g. release protocols, certificate of anal ysis) and 
the required approvals have been obtained .
The vaccines are labelled and packed according to applicable regulatory  requirements.
Commercial vaccine(s) are assumed to comply with the specifications given in the 
manufacturer‚Äôs Summary of Product Characteristics.
The characteristics of the s tudy vaccines are presented in Table 14.
Table 14 Study  vaccines
Treatment 
nameVaccine 
nameFormulation PresentationVolume to be 
administeredNo. of 
doses
HZ/su VZV gE gE=50¬µg per 0.5 mL of 
reconstituted vaccineLyophilized pellet in 
a monodose vial
0.5 m L 2 AS01 B MPL=50¬µg; QS21=50¬µg; 
Liposomes per 0.5 mL of 
reconstituted vaccineLiquid in a 
monodose vial
Prevenar13 Prevenar13 13 pneumococcal 13 
polysaccharides (1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 18C, 19A, 19F, 
23F), conjugated to cross -
reactive material 197 carrier 
protein and adsorbed on 
aluminum phosphate 
(PS1=2.2¬µg CRM197; 
PS3=2.2¬µg CRM197; 
PS4=2.2¬µg CRM197; 
PS5=2.2 ¬µg CRM197; 
PS6A=2.2¬µg CRM197; 
PS6B=4.4¬µg CRM197; 
PS7F=2.2¬µg CRM197; 
PS9V=2.2¬µg CRM197; 
PS14=2.2¬µg CRM197; 
PS18C=2.2¬µg CRM197; 
PS19A=2.2¬µg CRM197; 
PS19F=2.2¬µg CRM197; 
PS23F=2.2¬µg CRM197; 
AlPO‚ÇÑ=125¬µg Al3+ )Homogenous white 
suspension after 
shaking (in pre -
filled syringe) 0.5 m L 1
HZ/su = Herpes Zoster subunit vaccine; VZV = Varicella Zoster Virus; gE = recombinant purified envelope glycoprotein
E; Œºg = microgram; mL = milliliter; AS01 B= Adjuvant System AS01 B; MPL: 3 -O-desacyl -4‚Äô-monophosphoryl lipid A.
*QS21: Quillaja saponaria Molina, fraction 21 (Licensed by GSK from Antigenics Inc, a wholly owned subsidiary of 
Agenus Inc., a Delaware, USA corporation).204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 586.2. Storage and handling of study  vaccine(s)
The study  vaccine(s) must be stored at the respective label storage temperature conditions 
in a safe and locked place. Access to the storage space should be limited to authorized 
study  personnel. The storage conditions will be assessed during pre- study  activities under 
the responsibility  of the sponsor study  conta ct. The storage temperature should be 
continuously  monitored with calibrated (if not validated) temperature monitoring 
device(s) and recorded. Refer to the SPM for more details on storage of the study  
vaccine(s) .
Temperature excursions must be reported in degree Celsius.
Any temperature excursion outside the range of 0.0 to +8.0 ÔÇ∞C (for +2 to +8¬∞C/+36 to 
+46¬∞F label storage condition) impacting investigational medicinal products (I MPs) must 
be reported in the appropriate (electronic) temperature excursion de cision form ([e]TDF). 
The impacted IMPs must not be used and must be stored in quarantine at label 
temperature conditions until usage approval has been obtained from the sponsor .
In case of temperature excursion below +2.0¬∞C down to 0.0¬∞C impacting IMP(s) there is 
no need to report in (e)TDF, but adequate actions must be taken to restore the +2 to 
+8¬∞C/+36 to +46¬∞F label storage temperature conditions. The impacted I MP(s) may  still 
be administered, but the site should avoid re -occurrence of such temperature excursion.
Refer to the SPM for more details on actions to take.
Refer to the SPM for details and instructions on the temperature excursion reporting and 
usage decision process, packaging and account ability  of the stud y vaccine(s) .
6.3. Dosage and administration of study  vaccine s
For HZ/su:
After reconstitution, the vaccine should be used promptly ; if this is not possible, the 
vaccine should be stored in a refrigerator (2¬∞C ‚Äì 8¬∞C). If not used within 6 hours it should 
be discarded. 
For Prevenar13 :
Prevenar13 is a commercially  available vaccine and should be administered in 
accordance with the instructions provided in the manufacturer‚Äôs product label/packaging 
insert.
Both vaccines will be administered as indicated in Table 15 and Table 16. The vaccines 
should be administered by  IM injection into the del toid muscle of different arms, using a 
standard aseptic technique. For subjects in the Co- Ad group at Visit Day  1, the HZ/su and 
Prevenar13 vaccinations must be administered in different arms. 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 59Table 15 Dosage and administration for the Co- Ad group
Type of 
contact and 
timepointTreatment 
nameVolume to be 
administeredRouteSite
Location Laterality
Visit Day 1 HZ/su 0.5ml IM Deltoid Non-dominant
Prevenar13 0.5ml IM Deltoid Dominant
Visit Month 2 HZ/su 0.5ml IM Deltoid Non-dominant1
IM: Intramuscular.
1In rare situations when there is no alternative, the injection may be given in the other arm.
Table 16 Dosage and administration for the Control group
Type of 
contact and 
timepointTreatment 
nameVolume to be 
administeredRouteSite
Location Laterality1
Visit Day 1 Prevenar13 0.5ml IM Deltoid Dominant
Visit Month 2 HZ/su 0.5ml IM Deltoid Non-dominant
Visit Month 4 HZ/su 0.5ml IM Deltoid Non-dominant
IM: Intramuscular.
1In rare situations when there is no alternative, the injection may be given in the other arm
6.4. Replacement of unusable vaccine doses
In addition to the vaccine doses provided for the planned number of subjects (including 
over-randomization when applicable), at least 30% additional vaccine doses will be 
supplied to replace those that are unusable. 
6.5. Contraindications to subsequent vaccination
The following events constitute absolute contraindica tions to further administration of the 
HZ vaccine. If any of these events occur during the study, the subject must not receive 
additional doses of vaccine but may  continue other study  procedures at the discretion of 
the investigator (see Section 8.5). 
ÔÇ∑Anaph ylaxis following the administration of vaccine(s).
ÔÇ∑Pregnancy .
ÔÇ∑If the subject experiences an SAE judged to be vaccine -related b y the investigator.
ÔÇ∑The occurrence of a new potential immune -mediated diseases (pIMDs) or the 
exacerbation of an existing pIMD that, in the opinion of the investigator, expose the 
subject to unacceptable risk from subsequent vaccination. I n such cases, the 
investigator shoul d use his/her clinical judgement prior to administering the next 
dose of the vaccine(s)/product(s). 
Refer to Section 8.1.5.1 for the definition of pIMDs.
ÔÇ∑Any confirmed or suspected immunosuppressive or immunodeficient condition, 
including HIV infection. 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 60ÔÇ∑Any condition that in the judgment of the investigator would make intramuscular 
injection unsafe.
ÔÇ∑If the subject experiences an event of HZ between the first and the second dose of 
HZ/su or between Visit Day 1 and an y dose of HZ/su vaccine (Refer Section 5.5and 
6.8).
The following events constitute contraindications to administration of HZ/su study  
vaccine at that point in time; if any  of these events occur at the time scheduled for 
vaccination, the subject may  be vaccinated at a later date, within the time window 
specified in the protocol, or withdrawn at the discretion of the investigator (Time 
windows between visits are given in Table 8and Table 9).
ÔÇ∑Acute disease and/or fever at the time of vaccination. 
ÔÄ≠Fever is defined as temperature ÔÇ≥38.0¬∞C / 100.4¬∞F. The preferred location for 
measuring temperature in this study  will be oral.
ÔÄ≠Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory  
infection) without fever can be administered all vaccines/products.
6.6. Warnings and precautions
Refer to the approved product label/package insert of Prevenar13 .
6.7. Concomitant medication s/product sand concomitant 
vaccinations
At each study  visit/contact, the investigator or delegate should question the subject about 
any medication s/product staken and vaccination sreceived b y the subject.
6.7.1. Recording of concomitant medications/products and 
concomitant vaccination s
The following concomitant m edication (s)/product (s)/vaccine (s)must be recorded in 
the eCRF.
ÔÇ∑All concomitant medications/products, except vitamins and dietary  supplements, 
administered during 30 day s following each dose of study  vaccine (Day  1 to Day  
30).
ÔÇ∑Relevant medications/products administered during the period.
ÔÇ∑Any concomitant vaccination administered in the period starting 30 day s before the 
first dose of study  vaccine and ending 30 day s after the last dose, and an y 
concomitant vaccination against HZ or pneumo coccal vaccine (other than the study  
vaccines) during the study  period.
ÔÇ∑Prophy lactic medication (i.e. medication administered in the absence of ANY 
symptom and in anticipation of a reaction to the vaccination).204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 61E.g. an anti -pyretic is considered to be prop hylactic when it is given in the absence 
of fever and an y other s ymptom, to prevent fever from occurring [fever is defined as 
temperature ÔÇ≥38.0¬∞C/100.4¬∞F regardless the location of measurement]. The 
preferred location for measuring temperature in this stu dy will be the oral cavity .
ÔÇ∑Any concomitant medications/products/vaccines listed in Section 6.7.2.
ÔÇ∑Any concomitant medications/products/vaccines re levant to a SAE/pIMD to be 
reported as per protocol or administered during the study  period for the treatment of 
a SAE /pI MD. In addition, concomitant medications relevant to SAEs and pI MD 
need to be recorded on the expedited Adverse Event report.
ÔÇ∑Any conc omitant medication administered for the treatment of confirmed or 
suspected HZ or an y HZ -related complications (including pain) at an y time during 
the study  period. 
6.7.2. Concomitant medications/products/vaccines that may  lead to the 
elimination of a subject fr om per- protocol analy ses
The use of the following concomitant medications/products/vaccines will not require 
withdrawal of the subject from the study  but may  determine a s ubject‚Äôs evaluability  in the 
per-protocol analysis. See Section 10.4 for cohorts to be anal ysed.
ÔÇ∑Any investigational or non- registered product (drug or vaccine) other than the study  
vaccine(s) used during the study  period. 
ÔÇ∑Immunosuppressants or other immune -modify ing drugs administered chronically  
(i.e. >14 day s in total) up to the last blood sampling. For corticosteroids, this will 
mean prednisone ÔÇ≥20 mg/day , or equivalent. Inhaled and topical steroids are 
allowed.
ÔÇ∑Long -acting immune -modify ing drugs administered at any  time during the study  
period up to the last blood sampling (e.g. infliximab).
ÔÇ∑A vaccine not foreseen by the stud y protocol administered during the period starting 
30 day s before and ending 30 day s after the l ast dose of study  vaccine 
administration. 
In case an emergency  mass vaccination for an unforeseen public health threat (e.g.: a 
pandemic) is organized by the public health authorities, outside the routine 
immunization program, the time period described ab ove can be reduced if necessary  
for that vaccine provided it is licensed and used according to its Prescribing 
Information and according to the local governmental recommendations and provided 
a written approval of the Sponsor is obtained.
ÔÇ∑Immunoglobulins a nd/or any  blood products administered during the study  period up 
to the last blood sampling.
ÔÇ∑Receipt of a vaccine against HZ or VZV or pneumococcal vaccine other than the 
study  vaccine during the study  period.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 626.8. Intercurrent medical conditions that may  lead to elimination 
of a subject from per-protocol analy ses
At each stud y visit subsequent to the first vaccination/the vaccination visit ,it must be 
verified if the subject has experienced or is experiencing an y intercurrent medical 
condition (I MC). If it is the case, the condition(s) must be recorded in the eCRF. An I MC 
is defined as a condition that has the capability  of confounding the i mmune response to 
the study  vaccine or its interpretation. Subjects may be eliminated from the Per-protocol 
cohort for immunogenicity  if, during the study , they  incur an IMC. 
Examples of I MCs include cases of HZ or a confirmed or suspected immunosuppressi ve 
or immunodeficient condition resulting from disease (e.g., malignancy , HIV infection).
All IMCs including HZ will be recorded until Visit Month 3 for subjects in the Co -Ad 
group and Visit Month 5 for subjects in the Control group. All IMCs will be recor ded in 
AE/SAE screens as appropriate . 
Occurrences of HZ from Visit Month 3 (Co-Ad group) and Visit Month 5 (Control 
group) are to be reported till study  end (phone contact at Month 14 for the Co- Ad group 
and Month 16 for the Control group) but will not be considered as IMCs.
7. HEA LTH ECONOMICS
Not applicable.
8. SAFETY
The investigator or site staff is/are responsible for the detection, documentation and 
reporting of events meeting the criteria and definition of an adverse event (AE) or serious 
adverse event (S AE) as provided in this protocol. 
Each subject will be instructed to contact the investigator immediatel y should they  
manifest an y signs or s ymptoms they  perceive as serious.
8.1. Safet y definitions
8.1.1. Definition of an adverse event
An AE is an y untoward medical occurrence in a clinical investigation subject, temporall y 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product.
An AE can therefore be any  unfavourable and unintended sign (including an abnormal 
labora tory finding), s ymptom, or disease (new or exacerbated) temporall y associated with 
the use of a medicinal product. For marketed medicinal products, this also includes 
failure to produce expected benefits (i.e. lack of efficacy ), abuse or misuse. 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 63Examples of an AE include:
ÔÇ∑Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
ÔÇ∑New conditions detected or diagnosed after study vaccine(s) administration even 
though they  may  have been present prior to the start of the study .
ÔÇ∑Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
ÔÇ∑Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study
vaccine(s) or a concurrent medication (overdose per se should not be reported as an 
AE/SAE).
ÔÇ∑Signs, sy mptoms temporally  associated with study vaccine(s) administration.
ÔÇ∑Significant failure of expected pharmacological or biological action. 
ÔÇ∑Pre-or post -treatment events that occur as a result of protocol- mandated procedures 
(i.e. invasive procedures, modification of subject‚Äôs previous therapeutic regimen).
AEs to be recorded as endpoints (solicited AEs) are described in Section 8.1.3 . All other 
AEs will be recorded as UNSOLI CITED AEs.
Examples of an AE DO NOT include:
ÔÇ∑Medical or surgical procedures (e.g. endoscop y, appendectom y); the condition that 
leads to the procedure is an AE/SAE.
ÔÇ∑Situations where an untoward medical occurrence did not occur (e.g. social and/or 
convenience admission to a hospital, admission for routine examination).
ÔÇ∑Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen. 
ÔÇ∑Pre-existing conditions or signs and/or s ymptoms present in a subject prior to the 
firststudy  vaccination. These events will be recorded in the medical history  section 
of the eCRF.
8.1.2. Definition of a serious adverse event 
A SAE is any  untoward medical occurrence that:
a.Results in death,
b.Is life -threatening,
Note: The term ‚Äòlife-threatening‚Äô in the definition of ‚Äòserious‚Äô refers to an event in 
which the subject was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, had it been more severe.
c.Requires hospitalization or prolongation of existing hospitalization ,
Note: I n general, hospitalization signifies that the subject has been admitted at the 
hospital or emergency  ward for observation and/or treatment that would not have 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 64been appropriate in the phy sician‚Äôs office or in an out -patient setting. Complications 
that occur during hospitalization are also considered AEs. If a complication prolongs 
hospitalization or fulfils any other serious criteria, the event will also be considered 
serious. When in doubt as to whether ‚Äò hospitalization ‚Äô occurred or was necessary , the 
AE should be considered serious.
Hospitalization for elective treatment of a pre- existing condition (known or 
diagnosed prior to informed consent signature) that did not worsen from baseline is 
NOT considered an AE.
d.Results in disability /incapacity , OR
Note: The term disability means a substantial disruption of a person‚Äôs ability to 
conduct normal life function s. This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhoea, influenza like illness, and accidental trauma (e.g. sprained 
ankle) which may  interfere or preve nt every day life functions but do not constitute a 
substantial disruption.
e.Is a congenital anomal y/birth defect in the offspring of a study subject.
Medical or scientific judgement should be exercised in deciding whether reporting is 
appropriate in other s ituations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may jeopardise the 
subject or may  require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These should also be considered serious. 
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or convulsions 
that do not result in hospitalization .
8.1.3. Solicited adverse events
Solicited local (injection -site) adverse events 8.1.3.1.
The following local (injection -site) AEs will be solicited:
Table 17 Solicited local adverse events
Pain at injection site
Redness at injection site
Swelling at injection site204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 65Solicited general adverse events 8.1.3.2.
The following general AEs will be solicited:
Table 18 Solicited general adverse events
Fatigue
Fever
Gastrointestinal symptoms‚Ä†
Headache
Myalgia
Shivering
‚Ä†Gastrointestinal symptoms include nausea, vomiting, diarrhoea and/or abdominal pain.
Note : Subjects will be instructed to measure and record the oral bod y temperature in the 
evening. Should additional temperature measurements be performed at other times of
day, subjects will be instructed to record the highest temperature in the diary card.
8.1.4. Clinical laboratory  parameters and other abnormal assessments 
qualify ing as adverse events or serious adverse events 
In absence of diagnosis, abnormal laboratory  findin gs (e.g. clinical chemistry , 
haematology , urinal ysis) or other abnormal assessments that are judged b y the 
investigator to be clinically  significant will be recorded as AE or SAE if they meet the 
definition of an AE or SAE (refer to Section s8.1.1 and 8.1.2). Clinically  significant 
abnormal lab oratory  findings or other abnormal assessments that are present at baseline 
and significantly  worsen following the start of the study  will also be reported as AEs or 
SAEs. However, clinically significant abnormal laboratory findings or other abnormal 
asses sments that are associated with the disease being studied, unless judged by  the 
investigator as more severe than expected for the subject‚Äôs condition, or that are present 
or detected at the start of the study and do not worsen, will not be reported as AEs or 
SAEs.
The investigator will exercise his or her medical and scientific judgement in deciding 
whether an abnormal laboratory  finding or other abnormal assessment is clinically  
significant.
8.1.5. Adverse events of specific interest
Potential immune -mediated dis eases 8.1.5.1.
Potential immune -mediated diseases (p IMDs) are a subset of AEs that include 
autoimmune diseases and other inflammatory  and/or neurologic disorders of interest 
which may  or may  not have an autoimmune aetiology . AEs that need to be recorded and 
reported as pIMDs include those listed in Table 19 .
However, the investigator will exercise his/her medical and scientific judgement in 
deciding whether other diseases have an autoimmune origin (i.e. pathoph ysiology  
involving sy stemic or organ -specific pathogenic autoantibodies) and should also be 
recorded as a p IMD.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 66Table 19 List of potential immune -mediated diseases
Neuroinflammatory disorders Musculoskeletal disorders Skin disorders
ÔÇ∑ Cranial nerve disorders, 
including paralyses/paresis (e.g. 
Bell‚Äôs palsy) 
ÔÇ∑ Optic neuritis
ÔÇ∑ Multiple sclerosis
ÔÇ∑ Transverse myelitis
ÔÇ∑ Guillain -Barr√© syndrome, 
including Miller Fisher syndrome 
and other variants
ÔÇ∑ Acute disseminated 
encephalomyelitis, including sit e 
specific variants: e.g. non -
infectious encephalitis, 
encephalomyelitis, myelitis, 
myeloradiculoneuritis
ÔÇ∑ Myasthenia gravis, including 
Lambert -Eaton myasthenic 
syndrome 
ÔÇ∑ Immune -mediated peripheral 
neuropathies and plexopathies, 
(including chronic inflammat ory 
demyelinating polyneuropathy, 
multifocal motor neuropathy and 
polyneuropathies associated 
with monoclonal gammopathy).
ÔÇ∑ NarcolepsyÔÇ∑ Systemic lupus 
erythematosus and 
associated conditions
ÔÇ∑ Systemic scleroderma
(Systemic sclerosis) , 
including diffuse systemic 
form and CREST syndrome
Idiopathic inflammatory 
myopathies, including 
dermatomyositis 
ÔÇ∑ Polymyositis 
ÔÇ∑ Antisynthetase syndrome
ÔÇ∑ Rheumatoid arthritis, and 
associated conditions 
including j uvenile chronic 
arthritis and Still‚Äôs disease
ÔÇ∑ Polymyalgia rheumatica
ÔÇ∑ Spondyloarthritis, including 
ankylosing spondylitis, 
reactive arthritis (Reiter's 
Syndrome) and 
undifferentiated 
spondyloarthritis 
ÔÇ∑ Psoriatic arthropathy
ÔÇ∑ Relapsing polychondritis
ÔÇ∑ Mixed connective tissue 
disorderÔÇ∑ Psoriasis
ÔÇ∑ Vitiligo
ÔÇ∑ Erythema nodos um
ÔÇ∑ Autoimmune bullous 
skin diseases 
(including pemphigus, 
pemphigoid and 
dermatitis 
herpetiformis)
ÔÇ∑ Alopecia areata
ÔÇ∑ Lichen planus
ÔÇ∑ Sweet‚Äôs syndrome
ÔÇ∑ Localised Scleroderma 
(Morphoea )
Vasculitides Blood disorders Others
ÔÇ∑ Large vessels vasculitis 
including: giant cell arteritis 
such as Takayasu's arteritis 
and temporal arteritis. 
ÔÇ∑ Medium sized and/or small 
vessels vasculitis including: 
polyarteritis nodosa, 
Kawasaki's disease, 
microscopic polyangiitis, 
Wegener's granulomato sis, 
Churg ‚ÄìStrauss syndrome 
(allergic granulomatous 
angiitis), Buerger‚Äôs disease 
(thromboangiitis obliterans), 
necrotizing vasculitis and anti-
neutrophil cytoplasmic 
antibody (ANCA) positive 
vasculitis (type unspecified), 
Henoch -Schonlein purpura, 
Behcet's syndrome, 
leukocytoclastic vasculitis.ÔÇ∑ Autoimmune 
hemolytic anemia
ÔÇ∑ Autoimmune 
thrombocytopenia
ÔÇ∑ Antiphospholipid 
syndrome
ÔÇ∑ Pernicious anemia
ÔÇ∑ Autoimmune aplastic 
anaemia
ÔÇ∑ Autoimmune 
neutropenia 
ÔÇ∑ Autoimmune 
pancytopeniaÔÇ∑ Autoimmune glomerulonephritis 
(including IgA nephropathy, 
glomerulonephritis rapidly 
progressive, membranous 
glomerulonephritis, 
membranoproliferative 
glomerulonephritis, and 
mesangioproliferative 
glomerulonephritis)
ÔÇ∑ Ocular autoimmune diseases 
(including a utoimmune uveitis and 
autoimmune retinopathy)
ÔÇ∑ Autoimmune 
myocarditis/cardiomyopathySarco
idosis
ÔÇ∑ Stevens- Johnson syndrome
ÔÇ∑ Sj√∂gren‚Äôs syndrome
ÔÇ∑ Idiopathic pulmonary fibrosis
ÔÇ∑ Goodpasture syndrome
ÔÇ∑ Raynaud‚Äôs phenomenon204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 67Liver disorders Gastrointestinal disorders Endocrine disorders
ÔÇ∑ Autoimmune hepatitis
ÔÇ∑ Primary biliary 
cirrhosis
ÔÇ∑ Primary sclerosing 
cholangitis
ÔÇ∑ Autoimmune 
cholangitisÔÇ∑ Inflammatory Bowel disease, 
including Crohn‚Äôs disease, 
ulcerative colitis,
microscopic colitis, 
ulcerative proctitis 
ÔÇ∑ Celiac disease
ÔÇ∑ Autoimmune pancreatitisÔÇ∑ Autoimmune thyroiditis (including 
Hashimoto thyroiditis)
ÔÇ∑ Grave's or Basedow‚Äôs disease
ÔÇ∑ Diabetes mellitus type I
ÔÇ∑ Addison‚Äôs disease
ÔÇ∑ Polyglandular autoimmune 
syndrome
ÔÇ∑ Autoimmune hypophysitis
When there is enough evidence to make any of the above diagnoses, the AE must be 
reported as a pIMD. S ymptoms, signs or conditions which might (or might not) represent 
the above diagnoses, should be recorded and reported as AEs but not as pIMDs until the 
final or definitive diagnosis has been determined, and alternative diagnoses have been 
eliminated or shown to be less likely .
In order to facilitate the documentation of pIMDs in the eCRF , a pIMD standard 
questionnaire and a list of preferred terms (PTs) and PT codes corresponding to the above 
diagnoses will be available to investigators at study  start.
8.2. Events or outcomes not qualify ing as adverse events or 
serious adverse events
8.2.1. Pregnancy
Female subjects who are pregnant or lactating at the time of vaccina tion must not receive 
additional doses of study  vaccine (s) but may  continue other study  procedures at the 
discretion of the investigator.
While pregnancy  itself is not considered an AE or SAE, any  adverse pregnancy  outcome 
or complication or elective termi nation of a pregnancy  for medical reasons will be 
recorded and reported as an AE or a SAE.
Note: The pregnancy  itself should alway s be recorded on an electronic pregnancy  report.
The following should alway s be considered as SAE and will be reported as desc ribed in 
Sections 8.4.1 and 8.4.3 :
ÔÇ∑Spontaneous pregnancy  loss, including:
spontaneous abortion, (spontaneous pregnancy  loss before/at 22 weeks of gestation)
ectopic and molar pregnancy
stillbirth (intrauterine death of foetus after 22 weeks of gestation).
Note: the 22 weeks cut -off in gestational age is based on WHO -ICD 10 noted in the 
EMA Guideline on pregnancy  exposure [ EMA , 2006 ].It is recognized that national 
regulations might be different.
ÔÇ∑Any early neonatal death (i.e. death of a live born infant occurring within the first 7 
days of life). 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 68ÔÇ∑Any congenital anomal y or birth defect (as per [ CDC MACDP ] guidelines) 
identified in the offspring of a study  subject (either during pregnancy , at birth or 
later) regardless of whether the foetus is delivered dead or alive. This includes 
anomalies id entified b y prenatal ultrasound, amniocentesis or examination of the 
products of conception after elective or spontaneous abortion.
Furthermore, an y SAE occurring as a result of a post -study  pregnancy  AND considered 
by the investigator to be reasonabl y related to the study vaccine(s) will be reported to 
GSK Biologicals as described in Section 8.4.3 . While the investigator is not obligated to 
activel y seek this information from former stud y participants, he/she may learn of a 
pregnancy  through spontaneous reporting.
8.3. Detecting and recording adverse events, serious adverse 
events and pregnancies
8.3.1. Time period for detecting and recording adverse events, seri ous 
adverse events and pregnancies
All AEs starting within 30 day s following administration of each dose of study  vaccine 
must be recorded into the appropriate section of the eCRF, irrespective of intensity  or 
whether or not they  are considered vaccination- related.
The time period for collecting and recording SAEs will begin at the first receipt of study  
vaccine and will end approximately  12 months following administration of the last dose 
of study  vaccine for each subject. See Section 8.4for instructions on reporting of SAEs.
All AEs/SAEs leading to withdrawal from the study  will be collected and recorded from 
the time of the first receipt of study  vaccine.
SAEs that are related to the study vaccine(s) will be collected and recorded from the time 
of the first receipt of study  vaccine(s) until the subject is discharged from the study .
In addition to the above -mentioned reporting requirements and in order to fulfil 
international reporting obligations, SAEs that are related to study  participation (i.e. 
protocol -mandated procedures, invasive tests, a change from existing therapy ) or are 
related to a concurrent GSK medication/vaccine will be collected an d recorded from the 
time the subject consents to participate in the study until she/he is discharged from the 
study .
The time period for collecting and recording pregnancies will begin at the first receipt of 
study  vaccine and will end approximately  12 months following administration of the last 
dose of study  vaccine. See section 8.4 for instructions on reporting of pregnancies.
The time period for c ollecting and recording of pIMDs will begin at the first receipt of 
study  vaccine and will end approximately  12 months following administration of the last 
dose of study  vaccine. See section 8.4 for instructions on reporting of pIMDs.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 69Intercurrent medical conditions other than HZ (see Section 6.8) will be recorded from 
Day 1 until Month 3 for subjects from the Co-Ad group and Month 5 for subjects from 
the Control group. Intercurrent medical conditions will be recorded in AE/SAE screens as 
appropriate.
The occurrence of HZ will constitute an AE/S AE as appropriate. The reporting period for 
cases of HZ will be from Day  1to study  end.
An overview of the protocol -required reporting periods for AEs, SAEs, pIMDs, 
pregnancies, and intercurrent medical conditions (including HZ) is given in Table 20.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 718.3.2. Post -Study adverse events and serious adverse events
A post -study  AE/SAE is defined as any  event that occurs outside of the AE/SAE 
reporting period defined inTable 20. Investigators are not obligated to actively seek AEs 
or SAEs in former stud y participants. However, if the investigator learns of any SAE at 
any time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to t he study vaccine (s), the investigator will promptly  notify  the 
Study  Contact for Reporting SAEs.
8.3.3. Evaluation of adverse events and serious adverse events
Active questioning to detect adverse events and serious adverse 8.3.3.1.
events
As a consistent method of collec ting AEs, the subject should be asked a non -leading 
question such as:
‚ÄòHave you felt different in any way since receiving the vaccine (s)or since the previous 
visit?‚Äô
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documen tation (e.g. hospital progress notes, laboratory and diagnostics reports) relative 
to the event. The investigator will then record all relevant information regarding an 
AE/SAE in the eCRF. T he investigator is not allowed to send photocopies of the 
subject‚Äô s medical records to GSK Biologicals instead of appropriatel y completing the 
eCRF . However, there may  be instances when copies of medical records for certain cases 
are requested b y GSK Biologicals. In this instance, all subject identifiers will be blinded 
on the copies of the medical records prior to submission to GSK Biologicals.
The investigator will attempt to establish a diagnosis pertaining to the event based on 
signs, s ymptoms, and/or other clinical information. I n such cases, the diagnosis should be 
documented as the AE/SAE and not the individual signs/symptoms.
Assessment of adverse events 8.3.3.2.
8.3.3.2.1. Assessment of intensity
The intensity  of the following solicited AEs will be assessed as described:204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 72Table 21 Intensity  scales for solicited symptoms in adults 
Adults
Adverse Event Intensity grade Parameter
Pain at injection site 0 None
1 Mild: Any pain neither interfering with nor preventing 
normal every day activities.
2 Moderate: Painful when limb is moved and 
interferes with every day activities.
3 Severe: Significant pain at rest. Prevents normal 
every day activities.
Redness at injection site Record greatest surface diameter in mm
Swelling at injection site Record greatest surface diameter in mm
Fever* Record temperature in ¬∞C/¬∞F
Headache 0 Normal
1 Mild: Headache that is easily tolerated
2 Moderate: Headache that interferes with normal 
activity
3 Severe: Headache that prevents normal activity
Fatigue 0 Normal
1 Mild: Fatigue that is easily tolerated
2 Moderate: Fatigue that interferes with normal activity
3 Severe: Fatigue that prevents normal activity
Gastrointestinal symptoms 0 Gastrointestinal symptoms normal
(nausea, vomiting, diarrhoea and/or 
abdominal pain)1 Mild: Gastrointestinal symptoms that are easily 
tolerated
2 Moderate: Gastrointestinal symptoms that interfere 
with normal activity
3 Severe: Gastrointestinal symptoms that prevent 
normal activity
Myalgia 0 Normal
1 Mild: Myalgia that is easily tolerated
2 Moderate: Myalgia that interferes with normal 
activity
3 Severe: Myalgia that prevents normal activity
Shivering 0 None
1 Shivering that is easily tolerated
2 Shivering that interferes with normal activity
3 Shivering that prevents normal activity
*Fever is defined as temperature ÔÇ≥38.0¬∞C / 100.4¬∞F. The preferred location for measuring temperature in this study 
will be the oral cavity. When there is no other alternative, the temperature may be recorded by other route. If the 
temperature is taken by an other route (axillary, rectal or tympanic), the route should be documented .
The maximum intensity  of local injection site redness/swelling will be scored at GSK 
Biologicals using GSK Biologicals‚Äô standard grading scale base on the US FDA 
guidelines for Tox icity Grading Scale for Healthy  Adult and Adolescent Volunteers 
enrolled in Preventive Vaccine Clinical Trials [ FDA , 2007].
0 : < 20 mm diameter
1 : ÔÇ≥20 mm to ÔÇ£50 mm diameter
2 : > 50 mm to ÔÇ£100 mm diameter
3 : > 100 mm diameter204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 73The investigator will assess the maximum intensity that occurred over the duration of the 
event for all unsolicited AEs (including SAEs) recorded during the stud y. The assessment 
will be based on the investigator‚Äôs clinical judgement.
The intensity  should be assigned to one of the following categories:
1 (mild) =An AE which is easil y tolerated b y the subject, causing minimal 
discomfort and not interfering with every day activities.
2 (moderate) =An AE which is sufficiently  discomforting to interfere with 
normal every day activities.
3 (severe) =An AE which prevents normal, every day activities (such an AE 
would, for example, prevent attendance at work/school and would 
necessitate the administration of corrective therapy .)
An AE that is assessed as Grade 3 (severe) should not be confused with a SAE. Grade 
3 is a category  used for rating the intensit y of an event; and both AEs and SAEs can be 
assessed as Grade 3. An event is defined as ‚Äòserious‚Äô when it meets one of the pre -
defined outcomes as described in Section 8.1.2 .
8.3.3.2.2. Assessment of causality
The investigator is obligated to assess the relati onship between study  vaccine(s) and the 
occurrence of each AE/SAE using clinical judgement. I n case of concomitant 
administration of multiple vaccines/products, if possible, the investigator should specify  
if the AE could be causally  relat ed to a specific vaccine/product administered (i.e 
investigational, control/placebo or co -administered vaccine). When causal relationship to 
a specific vaccine(s)/product(s) cannot be determined the investigator should indicate the 
AE to be related to all products.
Alternative plausible causes, such as natural history of the underl ying diseases, 
concomitant therap y, other risk factors, and the temporal relationship of th e event to the 
study  vaccine(s) will be considered and investigated. The investigator w ill also consult 
the IB and/or and/or SmPC and/or Prescribing In formation for marketed products to 
determine his/her assessment.
There may  be situations when a SAE has occurred and the investigator has minimal 
information to include in the initial report t o GSK Biologicals. However, it is very  
important that the investigator alway s makes an assessment of causality  for every  event 
prior to submission of the Expedited Adverse Events Report to GSK Biologicals. The 
investigator may  change his/her opinion of cau sality  in light of follow -up information and 
update the SAE information accordingl y. The causality assessment is one of the criteria 
used when determining regulatory  reporting requirements.
All solicited local (injection site) reactions will be considered causall y related to 
vaccination. Causality of all other AEs should be assessed by the investigator using the 
following question:204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 74Is there a reasonable possibility that the AE may have been caused by the study vaccine?
YES :There is a reasonable possibilit y that the study vaccine(s)
contributed to the AE. 
NO :There is no reasonable possibility that the AE is causally  related to 
the administration of the study  vaccine(s) . There are other, more 
likely  causes and administration of the study  vaccine (s)is not 
suspected to have contributed to the AE.
If an event meets the criteria to be determined as ‚Äòserious‚Äô (see Section 8.1.2 ), additional 
examinations/tests will be performed b y the investigator in order to determine ALL 
possible contributing factors for each SAE.
Possible contributing factors include:
ÔÇ∑Medical hist ory.
ÔÇ∑Other medication.
ÔÇ∑Protocol required procedure.
ÔÇ∑Other procedure not required by  the protocol.
ÔÇ∑Lack of ef ficacy  of the vaccine(s) , if applicable.
ÔÇ∑Erroneous administration.
ÔÇ∑Other cause (specify ).
Assessment of outcomes 8.3.3.3.
The investigator will assess the outcome of all unsolicited AEs (including SAEs) 
recorded during the study as:
ÔÇ∑Recovered/resolved.
ÔÇ∑Recovering/resolving.
ÔÇ∑Not recovered/not resolved.
ÔÇ∑Recovered with sequelae/resolved with sequelae.
ÔÇ∑Fatal (SAEs onl y).
Medically  attended visits 8.3.3.4.
For each solicite d and unsolicited sy mptom the subject experiences, the subject will be 
asked if he/she received medical attention defined as hospitalization , or an otherwise 
unscheduled visit to or from nurses practitioners, health care workers or medical 
personnel for an y reason , including emergency  room visits. This information will be 
recorded in the in the eCRF . 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 758.4. Reporting of serious adverse events, pregnancies, and 
other events
8.4.1. Prompt reporting of serious adverse events, pregnancies, and 
other events to GSK Biologicals
SAEs that occur in the time period defined in Section 8.3will be reported promptly  to 
GSK within the timeframes described in Table 22, once the investigator determines that 
the event meets the protocol definition of a SAE.
Pregnancies that occur in the time period defined in Section 8.3will be reported promptly  
to GSK within the timeframes described in Table 22, once the investigator becomes 
aware of the pregnancy . 
pIMDs that occur in the time period defined in Section 8.3 will be reported promptly  to 
GSK within the timeframes described in Table 22, once the investigator determines that 
the event meets the protocol definition of a pIMD .
Table 22 Timeframes for submitting serious adverse event, pregnancy  and 
other events reports to GSK Biologicals
Type of EventInitial ReportsFollow -upof Relevant Information on a Previous 
Report
Timeframe Documents Timeframe Documents
SAEs 24 hours*‚Ä° electronic Expedited 
Adverse Events Report24 hours* electronic Expedited Adverse 
Events Report
Pregnancies 2 weeks* electronic pregnancy report 2 weeks* electronic pregnancy report
pIMDs 24 hours**‚Ä°electronic Expedited 
Adverse Events Report24 hours* electronic Expedited Adverse 
Events Report
* Timeframe allowed after receipt or awareness of the information.
**Timeframe allowed once the investigator determines that the event meets the protocol definition of a pIMD .
‚Ä° The investigator will be required to confirm review of the SAE/pIMD causality by ticking the ‚Äòreviewed‚Äô box in the 
electronic Expedited Adverse Events Report within 72 hours of submission of the SAE/pIMD204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 778.4.4. Completion and transmission of pregnancy  reports to GSK 
Biologicals
Once the investigator becomes aware that a subject is pregnant, the investigator (or 
designate) must complete the required information onto the electronic pregnancy  report 
WITHIN 2 WEEKS.
Note: Conventionally , the estimated gestational age (EGA) of a pregnancy is dated from 
the first day  of the last menstrual period (LMP) of the cy cle in which a woman conceives. 
If the LMP is uncertain or unknown, dating of EGA and the estimated date of delivery  
(EDD) should be estimated by  ultrasound examination and recorded in the pregnancy  
report.
8.4.5. Reporting of pIMDs to GSK Biologicals
Once a p IMD is diagnosed (serious or non- serious) in a study  subject, the investigator (or 
designate) must complete the information in the electronic Expedited Adverse Events 
Report WITHIN 24 HOURS after he/she becomes aware of the diagnosis. The report 
allows to specify  that the event is a pIMD and whether it is serious or non serious. The 
report will alway s be completed as thoroughly  as possible with all available details of the 
event, in accordance with the pI MD standard questionnaire provided. Even if the 
investigator does not have all information regarding a p IMD, the report should still be 
completed within 24 hours. Once additional relevant information is received, the report 
should be updated WI THIN 24 HOURS.
The investigator will alway s provide an assessment of causalit y at the time of the initial 
report. The investigator will be required to confirm the review of the pIMD causalit y by 
ticking the ‚Äòreviewed‚Äô box in the electronic Expedited Adverse Events Report within 72 
hours of submission of the pIMD.
Refer to Section 8.4.3.1 for back-up s ystem in case the electronic rep orting sy stem does 
not work.
8.4.6. Updating of SA E, pregnancy , and pIMD information after removal 
of write access to the subject‚Äôs eCRF
When additional SAE, pregnancy , or p IMD information is received after removal of the 
write access to the subject‚Äôs eCRF, new o r updated inf ormation should be recorded on the 
appropriate paper report , with all changes signed and dated by  the investigator. The 
updated report should be faxed to the Study  Contact for Reporting SAEs (refer to the 
Sponsor I nformation ) or to GSK Biologicals Clinical Safet y and Pharmacovigilance 
department within the designated reporting time frames specified in Table 22.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER -059 PRI)
Protocol Amendm ent 2 Final
30-JAN-2018 788.4.7. Regulatory  reporting requirements for serious adverse events
The investigator will promptly  report all SAEs to GSK in accordance with the procedures 
detailed in Section 8.4.1. GSK Biologicals has a legal responsibility to promptly  notify , 
as appropriate, both the local regulatory  authorit y and other regulatory  agen cies about the 
safet y of a product under clinical investigation. Prompt notification of SAEs by the 
investigator to the Stud y Contact for Reporting SAEs is essential so that legal obligations 
and ethical responsibilities towards the safet y of other subject s are met.
Investigator safety  reports are prepared according to the current GSK policy and are 
forwarded to investigators as necessary . An investigator safet y report is prepared for a 
SAE(s) that is both attributable to the study vaccine(s) and unexpected. The purpose of 
the report is to fulfil specific regulatory and GCP requirements, regarding the product 
under investigation.
8.5. Follow -up of adverse events, serious adverse events, and 
pregnancies
8.5.1. Follow -up of adverse events and serious adverse events 
Follo w-up during the study 8.5.1.1.
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject and provide additional relevant information on the subject‚Äôs condition to GSK 
Biologicals (within 24 hours for SAEs; refer to Table 22).
All SAEs and pI MDs (serious or non -serious) documented at a previous visit/contact and 
designated as not recovered/not resolved or recovering/resolving will be reviewed at 
subsequent visits/contacts until the last visit of the subject .
All AEs documented at a previous visit/contact and designated as not recovered/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until 30
days after the last vaccination .
Follo w-up after the subject is discharged from the study 8.5.1.2.
The investigator will follow subjects:
ÔÇ∑with SAEs, pI MDs (serious or non -serious) , or subjects withdrawn from the study  as 
a result of an AE, until the event has resolved, subsided, stabilised, disappeared, or 
until the event is otherwise explained, or the subject is lost to follow -up.
If the investigator receives additional relevant information on a previousl y reported SAE, 
he/she will provide this information to GSK Biologicals using a paper/ electronic 
Expedited Adverse Events Report and/or pregnancy report as applicable.
GSK Biologicals may  request that the investigator performs or arranges the conduct of 
additional clinical examinations/tests and/or evaluations to elucidate as fully as possible 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 79the nature and/or causality of the AE or SAE. The investigator is obliged to assist. I f a 
subject dies during participation in the study or during a recognised follow -up period, 
GSK Biologicals will be provided with an y available post -mortem findings, including 
histopathology .
8.5.2. Follow -up of pregnancies
Pregnant subjects will be followed to determine the outcome of the pregnancy . At the end 
of the pregnancy , whether full -term or premature, information on the status of the mo ther 
and child will be forwarded to GSK Biologicals using the electronic pregnancy  report and 
the Expedited Adverse Events Report if applicable. Generall y, the follow -up period 
doesn‚Äôt need to be longer than six to eight weeks after the estimated date of d elivery .
Regardless of the reporting period for SAEs for this study, if the pregnancy outcome is a 
SAE, it should alway s be reported as SAE.
8.6. Treatment of adverse events
Treatment of an y AE is at the sole discretion of the investigator and according to current 
good medical practice . Any medication admi nistered for the treatment of a SAE / pI MDs
should be recorded in Expedited Adverse Event Report of the subject‚Äôs eCRF (refer to 
Section 6.7).
8.7. Subject card
Study  subjects must be provided with the address and telephone number of the main 
contact for information about the clinical study .
The investigator (or designate) must therefore provide a ‚Äúsubject card‚Äù to each subject. In 
an emergency  situation this card serves to inform the responsible attending phy sician that 
the subject is in a clinical study  and that relevant information may  be obtained by  
contacting the investigator.
9. SUBJECT COMPLETION A ND WITHDRA WAL
9.1. Subject completion
A subject who returns for the concluding visit/is available for the concluding contact 
foreseen in the protocol is considered to have completed the study .
9.2. Subject w ithdrawal
Withdrawals will not be replaced.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 809.2.1. Subject w ithdrawal from the s tudy
From an anal ysis perspective, a ‚Äòwithdrawal‚Äô from the study  refers to any  subject who did 
not come back for the concluding visit/was not available for the concluding contact 
foreseen in the protocol. 
All data collected until the date of withdrawal/la st contact of the subject will be used for 
the anal ysis.
A subject is considered a ‚Äòwithdrawal‚Äô from the study  when no study  procedure has 
occurred, no follow -up has been performed and no further information has been collected 
for this subject from the date of withdrawal/last contact.
Investigators will make an attempt to contact those subjects who do not return for 
scheduled visits or follow -up. 
Information relative to the withdrawal will be documented in the eCRF. The investigator 
will document whether t he decision to withdraw a subject from the stud y was made by 
the subject himself/herself , or b y the investigator, as well as which of the following 
possible reasons was responsible for withdrawal:
ÔÇ∑Serious adverse event.
ÔÇ∑Unsolicited non -serious adverse even t.
ÔÇ∑Solicited adverse event
ÔÇ∑Protocol violation (specify ).
ÔÇ∑Consent withdrawal, not due to an adverse event*.
ÔÇ∑Moved from the stud y area.
ÔÇ∑Lost to follow -up.
ÔÇ∑Other (specify ).
*In case a subject is withdraw n from the study  because he/she has withdrawn consent, the 
investigator will document the reason for withdrawal of consent, if specified by  the 
subject, in the eCRF .
Subjects who are withdrawn from the study  because of SAEs/AEs must be clearl y 
distinguished from subjects who are withdrawn for other reasons. Investigators will 
follow subjects who are withdrawn from the study  as result of a SAE/AE until resolution 
of the event (see Section 8.5.1.2 ).204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 819.2.2. Subject w ithdrawal from study vaccine (s)
A ‚Äòwithdrawal‚Äô from the study vaccine (s)refers to any  subject who does not receive the 
complete treatment, i.e. when no further planned dose is administered from the date of 
withdrawal. A subject withdrawn from the study vaccine (s)may not necessarily  be 
withdrawn from the study as further stud y procedures or follow -up may  be performed 
(safet y or immunogenicity) if planned in the stud y protocol. 
Information relative to premature discontinuation of the study vaccine (s)will be 
documented on the Vaccine Administration screen of the eCRF. The investigator will 
document whether the decision to discontinue further vaccination/treatment was made b y 
the subject himself/herself , or b ythe investigator, as well as which of the following 
possible reasons was responsible for withdrawal:
ÔÇ∑Serious adverse event.
ÔÇ∑Unsolicited non -serious adverse event.
ÔÇ∑Solicited adverse event
ÔÇ∑Not willing to be vaccinated
ÔÇ∑Other (specify ).
9.3. Extension study
During the study  conclusion visit/contact, the inv estigator will ask each subject if he/she 
is interested in participat ingin a long -term study . If a subject is not interested in 
participating in the long- term study  the reason for refusal will be documented in the 
subject‚Äôs e CRF.
10. STATISTICA L METHODS
10.1. Primary  endpoints
ÔÇ∑HZ/su immunogenicit y:
ÔÄ≠Vaccine response for anti -gE humoral immunogenicity , as determined b y ELISA, 
in subjects from the Co -Ad group at one month post -dose 2, at Visit Month 3.
ÔÄ≠Anti- gEantibody  concentrations as determined b y ELISA at one month post-
dose 2, at Visit Month 3 for the Co- Ad group and Visit Month 5 for the Control 
group.
ÔÇ∑Pneumococcal vaccine immunogenicit y:
ÔÄ≠Anti- pneumococcal antibody  titers for the 13 following seroty pes as determined 
by MOPA at one month post -dose at Visit Month 1: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 
14, 18C, 19A, 19F and 23F.
The criteria used to define the VRR is given in Section 10.7.1 .204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 8210.2. Secondary  endpoint s
ÔÇ∑Occurrence of solicited local and general s ymptoms : 
ÔÄ≠Occurrence, duration and intensity  of each solicited local symptom within 7 day s 
(Day s 1 - 7) after each vaccinat ion,
ÔÄ≠Occurrence, duration, intensity  and relationship to vaccination of each solicited 
general s ymptom within 7 day s (Day s 1 to 7) after each vaccination.
ÔÇ∑Occurrence of unsolicited AEs:
ÔÄ≠Occurrence, intensity and relationship to vaccination of unsol icited AEs within 
30 day s (Day s 1 to 30) after each vaccination, according to the Medical 
Dictionary  for Regulatory  Activities (MedDRA) classification.
ÔÇ∑Occurrence of SAEs:
ÔÄ≠Occurrence and relationship to vaccination of all SAEs from first vaccination a t 
Day 1 up to 30 day s post last vaccination.
ÔÄ≠Occurrence and relationship to vaccination of all SAEs during the period starting 
after 30 day s post last vaccination up to study  end.
ÔÇ∑Occurrence of pIMDs:
ÔÄ≠Occurrence and relationship to vaccination of an ypIMDs from first vaccination 
at Day  1 up to 30 day s post last vaccination.
ÔÄ≠Occurrence of an y pIMDs during the period starting after 30 day s post last 
vaccination up to study  end.
10.3. Determination of sample size
Assumptions used for the sample -size calcu lations come from data available from study  
Zoster -010 (112077) and the Prevenar13 assessment report [ EMA , 2011 ]which provides 
a summary  of the data used by  the Committee for Medicinal Products for Human Use 
(CHMP) of the European Medicines Agency  (EMA) to extend the indication of 
Prevenar13 to include adults aged ÔÇ≥50 YOA.
The evaluation of the VRR following administration of two doses of HZ/su will be one of 
the co- primary  objectives. The objective will be met if the LL of the 95% CI of VRR is 
equal to or more than 60% (criterion used in other studies in the HZ/su vaccine program). 
In the absence of correlate of protection or threshold level, this criterion ensures that an 
acceptable percentage of subjects meet GSK definition of responder (a 4 -fold increase in 
anibody  concentration/titer). Based on ZOS TER -010 (112077) study  results, the vaccine 
response assumed in healthy  adults ( ÔÇ≥50 years of age) is 95%.
The humoral immune responses to the 13 serot ypes of Prevenar13 one month post -dose 
and to HZ/su (anti -gE) one month post -dose 2 will be the two other co-primary  objectives 
and will be compared to demonstrate non -inferiority  of the Co-Ad to the Control groups.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 83Non-inferiority with respect to the antibod y responses to gE will be demonstrated if the 
ULs of the 95% CIs of the GMC ratios (Control group divid ed by Co -Ad group) are 
below the pre -defined clinical limit of 1.5 (based on variability  of the assay s used in the 
HZ/su vaccine program), one month post- dose 2 (Visit Month 3 for the Co -Ad group and 
Visit Month 5 for the Control group).
Non-inferiorit y with respect to the immune responses to the 13 vaccine pneumococcal 
seroty pes will be demonstrated if the UL of the 95% CI  of the MOPA GMTs ratios 
(Control group divided by Co -Ad group) is below the pre -defined clinical limit of 2 
(based on variability  of th e assay s used ) for each of 13 pneumococcal vaccine serot ypes, 
one month post -dose (Month 1).
No adjustment is needed for the type I error due to multiple comparison since fixed 
sequence test which allows full alpha propagation in pre- ordered family  of hy potheses 
will be used.
The global power to meet all co -primary  objectives with 410 evaluable subjects in Co -Ad 
and Control groups is approximately  91% ( Table 23). Assuming that about 10% of the 
subjects enrolled are non -evaluable (e.g. due to dropout, bad sample), approximately  912 
subjects will need to be enrolled (456 subjects in each treatment group).204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 84Table 23 Power to demonstrate VRR objective and non -inferiority  of the 
immunogenicity  of HZ/su and Prevenar13 co-administered 
compared to Control group
Family 1: HZ/su: VVR*(1 -sided test with alpha = 2.5%) 
Endpoint Threshold VR assumed Total ÔÅ¢ Power
VRR in Co -Ad group 0.60 95% 0.001% 99.99%
Family 2: HZ/su : non -inferiority* (1 -sided test with alpha = 2.5%) N=410 
Endpoint Standard deviation ÔÅ§ Total ÔÅ¢ Power
Anti-gE GMC ratio 0.35 1.5 0.001 % 99.99 %
Family 3: Prevenar13 : Non -inferiority* (1 -sided test with alpha = 2.5%)  N=410
Endpoint (13 vaccine 
pneumococcal serotypes)Standard deviation ÔÅ§ Total ÔÅ¢ Power
3 GMT ratio 0.660 2 0.001% 99.99%
19A GMT ratio 0.644 2 0.001% 99.99%
1 GMT ratio 0.798 2 0.029% 99.97%
18C GMT ratio 0.891 2 0.203% 99.80%
4 GMT ratio 0.906 2 0.260% 99.74%
6A GMT ratio 0.919 2 0.320% 99.68%
5 GMT ratio 0.931 2 0.383% 99.62%
19F GMT ratio 0.971 2 0.664% 99.33%
6B GMT ratio 0.995 2 0.891% 99.11%
7F GMT ratio 1.014 2 1.107% 98.89%
9V GMT ratio 1.021 2 1.194% 98.81%
14 GMT ratio 1.045 2 1.530% 98.47%
23F GMT ratio 1.094 2 2.398% 97.60%
Global ÔÅ¢to show non -inferiority ~9%
Global power ~91%
VRR: vaccine response rate; gE: Varicella Zoster Virus glycoprotein E; GMT: geometric mean titer; GMC: geometric 
mean concentration.
* Pass 12 ,alpha = 2.5%, for VRR: Exact test, for non -inferiority one -sided equivalence of means.
For gE: non -inferiority limit = 0.176 (=log10(1.5)), power under equal GMC
For each pneumococcal serotype: non -inferiority limit = 0.301 (=log10(2)), variability for each of the 13 vaccine 
pneumococcal serotype taken from the EMA assessment report for Prevenar13 and multiplied by 1.1, power 
under equal GMT.
10.4. Cohorts for A nalyses
10.4.1. Total vaccinated cohort
The Total vaccinated cohort (TVC) will include all subjects with at least one vaccine 
administration documented:
ÔÇ∑The TVC for anal ysis of reactogenicity  will include all subjects with at least one 
vaccine administered.
ÔÇ∑The TVC for analysis of safet y will include all subjects with at least one vaccine 
administered.
ÔÇ∑The TVC for anal ysis of immunogenicit y will include vaccinated subjects for whom 
immunogenicit y data are available.
The TVC anal ysis will be performed per treatment actual ly administered (at Dose 1).204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 8510.4.2. Per-protocol cohort for analy sis of immunogenicity
The Per-protocol cohort for anal ysis of immunogenicity  will include all evaluable 
subjects: 
ÔÇ∑who meet all eligibility  criteria,
ÔÇ∑who comply  with the procedures and intervals allowed for the anal ysis,
ÔÇ∑who do not meet an y of the criteria for elimination during the stud y,
ÔÇ∑for whom data concerning immunogenicit y endpoint measures are available.
10.5. Derived and transformed data
ÔÇ∑Immunogenicit y
The cut -off value is defined by  the laboratory  before the analy sis and is described in 
Section 5.8.3 .
10.5.1. Handling of missing data
For the anal ysis of s olicited sy mptoms, missing or non -evaluable measurements will not 
be imputed. Therefore, the anal ysis of the solicited sy mptoms based on the TVC will 
include only  subjects/doses with documented safety  data (i.e. s ymptom screen 
completed).
For the anal ysis of unsolicited AEs/SAEs/pI MDs/concomitant medication, all vaccinated 
subjects will be considered and subjects who did not report an event will be considered as 
subjects without an event.
For a given subject and a given immunogenicit y measurement, missing o r non -evaluable 
measurements will not be replaced. Therefore, a subject will be excluded from an 
analysis if all measurements are missing or non -evaluable.
10.6. Analysis of demographics
Demographic characteristics (age, sex, race and ethnicity ) will be tabulated per treatment 
group. 
The mean age (plus range and standard deviation [SD]) of the enrolled subjects, as a 
whole, and per treatment group will be calculated. The distribution of subjects enrolled 
among the stud y sites will be tabulated as a whole and per treatment group.
The same tabulations might be performed b y age category if deemed necessary.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 8610.7. Analysis of immunogenicity
The primary  anal ysis will be based on the per-protocol cohort for anal ysis of 
immunogenicit y. If, in a ny study  group, the percentage of enrolled subjects with 
serological results excluded from the per-protocol cohort for anal ysis of immunogenicit y 
is 5% or more, a second anal ysis based on the Total vaccinated cohort will be performed 
to complement the per-protocol analysis.
10.7.1. Humoral immune response
ÔÇ∑A seronegative subject is a subject whose antibodies concentration/titer is below the 
cut-off value (cut -off value is defined by  the laboratory  prior to the analy sis).
ÔÇ∑A seropositive subject is a subject whose ant ibodies concentration/titer is greater 
than or equal to the assay cut- off value.
ÔÇ∑The seropositivity  rate is defined as the percentage of seropositive subjects.
ÔÇ∑The VRR for anti -gE is defined as the percentage of subjects who have at least:
ÔÄ≠a 4-fold increase in the anti -gE antibodies concentration as compared to the pre-
vaccination anti -gE antibodies concentration, for subjects who are seropositive at 
baseline, or,
ÔÄ≠a 4-fold increase in the anti -gE antibodies concentration as compared to the anti-
gE antibodie s cut-off value for seropositivity , for subjects who are seronegative 
at baseline.
ÔÇ∑The GMC/GMT calculations are performed b y taking the anti -log of the mean of the 
log concentration transformations. Antibody  concentrations below the cut- off of the 
assay  will be given an arbitrary  value equal to half the cut- off for the purpose of 
GMC/GMT calculation.
10.7.2. Statistical considerations for confirmatory objectives
All analy ses will be performed overall and by  age stratum, if the number of subjects 
enrolled is sufficient in each stratum.
For the multiplicity  adjustment, all hy potheses will be ranked into three families and one 
subfamily  according to the power of test ( Table 23 ). Fixed sequence testing which allows 
for full alpha propagation in pre- ordered hypotheses families will be applied in the 
following manner:
Family  1:
In the Co -Ad group, for anti -gE, at one month post- dose 2:
ÔÇ∑The VRR and 95% CI will be computed.
The objective is met if the LL of the 95% CI is ÔÇ≥60%. 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 87Family  2:
For anti -gE, at one month post -dose 2:
ÔÇ∑The 95% CI of the group GMCs ratio will be computed using an anal ysis of 
covariance (ANCOVA) model on the log10 transformation of the concentrations. 
The pre -vaccination log -transformed antibody  concentrations will be included as 
continuous covariate and t he ANCOVA model will include the vaccine group and 
age strata as fixed effects. 
In terms of concentrations, the Co -Ad group will be considered non -inferior to the 
Control group if the UL of the 95% CI for the GMC ratio of the Control group to the Co -
Ad group is <1.5.
Family  3:
For each vaccine pneumococcal serot ype (according to the order in Table 23 ), one month 
post-dose:
ÔÇ∑The 95% CI of the group MOPA GMT ratios will be computed using an AN COVA 
model on the log10 transformation of the titers. The pre -vaccination log -
transformed antibody titers will be included as a continuous covariate .The 
ANC OVA model will include the vaccine group and age strata as fixed effects. 
(Amended 30 January 2018)
In terms of MOPA GMTs, the Co-Ad group will be considered non- inferior to the Control 
group if the UL of the 95% CI for the MOPA GMTs ratio of the Control g roup to the Co-
Ad group is <2 for each of the 13 vaccine serotypes.
10.8. Analysis of safety
The anal ysis for safet y will be based on the TVC; all safet y analyses may also be 
performed b y age strata (50 -59, 60- 69 and ‚â•70 YOA).
When appropriate, tabulations will be presented overall and b y time of occurrence 
relative to last vaccination (e.g. using windows such as Day s 1 to 7, Day s 1 to 30 and 
more than 30 day s post -vaccination).
The results for the anal ysis of safet y will be tabulated as follows:
ÔÇ∑The number and p ercentage of subjects with at least one local solicited AE, with at 
least one general solicited AE, and with an y solicited AE during the 7 -day follow -up 
period with exact 95% CIs after each vaccine dose and overall by  vaccination group
will be provided;
ÔÇ∑The percentage of subjects reporting each individual solicited local and general AE 
during the solicited 7 -day follow -up period will be tabulated with exact 95% CI ;
ÔÇ∑ For all solicited s ymptoms, the same tabulation will be performed for grade 3 
solicited AEs and for solicited general AEs with relationship to vaccination;204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 88ÔÇ∑Number of day s with each individual solicited local and general AE during the 
solicited 7 -day follow -up period;
ÔÇ∑The proportion of subjects with at least one report of unsolicited AE classified by the 
MedDRA preferred term and reported up to 30 day s after each vaccination will be 
tabulated with exact 95% CI ;
ÔÇ∑The same tabulation will be performed for grade 3 unsolicited AEs and for 
unsolicited AEs with a relationship to vaccination. The proportio n of AEs resulting 
in a medically attended visit will also be tabulated;
ÔÇ∑Total number/percentages of doses (per dose and overall) followed b y AEs will be 
tabulated;
ÔÇ∑Number of subjects with pI MDs will be tabulated;
ÔÇ∑SAEs , including fatalities and withdrawal due to AE(s) will be described in detail.
10.9. Interpretation of analy ses
All co- primary  objectives will be evaluated using a one -sided Ty pe I error of 2.5% (as 
alread y justified b y fixed sequential testing procedure, no alpha adjustment needed) . The 
trial will be considered conclusive if all co- primary  objectives criteria are met.
10.10. Conduct of analy ses
Any deviation(s) or change(s) from the original statistical plan outlined in this protocol 
will be described and justified in the final study  repor t.
10.10.1. Sequence of analy ses
The anal ysis will be performed in the following steps:
1.Analysis of the co -primary immunogenicity objectives will be performed at the end 
of the active phase on data as clean as possible. A confirmatory re -analysis will be 
done at the end of the study using the final database . In addition, a nalyses of 
secondary objectives will also be performed at the end of the active phase. 
(Amended 30 January 2018) ..
2.Analy ses on safety  data will be performed when all data up to study  end (i.e., p hone 
contact at Month 14 for Co -Ad group and phone contact at Month 16 for Control 
group) will be available and cleaned. (Amended 30 January 2018)
An integrated clinical study  report containing all data will be written and made available 
to the investigato rs.
10.10.2. Statistical considerations for interim analyses
No interim anal yses are planned.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 8911. ADM INISTRA TIVE M ATTERS
To comply  with ICH GCP administrative obligations relating to data collection, 
monitoring, archiving data, audits, confidentiality, public disclosur e requirements and 
publications must be fulfilled. 
11.1. electronic Case Report Form instructions
A validated GSK defined electronic data collection tool will be used as the method for 
data collection. 
In all cases, subject initials will not be collected nor transmitted to GSK. Subject data 
necessary  for anal ysis and reporting will be entered/transmitted into a validated database 
or data s ystem. Clinical data management will be performed in accordance with 
applicable GSK standards and data cleaning procedures.
While completed eCRFs are reviewed b y a GSK Biologicals‚Äô Site Monitor at the study 
site, omissions or inconsistencies detected b y subsequent eCRF review may necessitate 
clarification or correction by  the investigator or appropriatel y qualified designee. In all 
cases, the investigator remains accountable for the study  data. 
The investigator will be provided with a CD-ROM of the final version of the data 
generated at the investigational site once the database is archived and the study  report is 
complete and approved by  all parties.
11.2. Stud y Monitoring by  GSK Biologicals
GSK will monitor the stud y to verify  that, amongst other items, the: 
ÔÇ∑Data are authentic, accurate, and complete.
ÔÇ∑Safety  and rights of subjects are being protected.
ÔÇ∑Study  is conducted in accordance with the currently  approved protocol, any other 
study  agreements, GCP and all applicable regulatory  requirements. 
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor dire ct access to all relevant documents.
The investigator must ensure provision of reasonable time, space and qualified personnel 
for monitoring visits.
Direct access to all stud y-site related and source data is mandatory  for the purpose of 
monitoring review. The monitor will perform a neCRF review and a Source Document 
Verification (SDV). By  SDV we understand verifying eCRF entries b y comparing them 
with the source data that will be made available by the investigator for this purpose. 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 90The Source Documentation Agreement Form describes the source data for the different 
data in the eCRF . This document should be completed and signed by  the site monitor and 
investigator and should be filed in the investigator‚Äôs study  file. Any data item for which 
the eCRF will serv e as the source must be identified, agreed and documented in the 
source documentation agreement form. 
Upon completion or premature discontinuation of the study , the monitor will conduct site 
closure activities with the investigator or site staff, as appro priate, in accordance with 
applicable regulations, GCP, and GSK procedures.
11.3. Record retention
Following closure of the study , the investigator must maintain all site study  records 
(except for those required by  local regulations to be maintained elsewhere) i n a safe and 
secure location. The records must be easily  accessible, when needed (e.g. audit or 
inspection), and must be available for review in conjunction with assessment of the 
facility , supporting s ystems, and staff. Where permitted by  applicable laws/ regulations or 
institutional policy , some or all of these records can be maintained in a validated format 
other than hard copy (e.g. microfiche, scanned, electronic); however, caution needs to be 
exercised before such action is taken. The investigator must ensure that all reproductions 
are legible and are a true and accurate cop y of the original and meet accessibility  and 
retrieval standards, including re -generating a hard copy, if required. Furthermore, the 
investigator must ensure that an acceptable back -up of the reproductions exists and that 
there is an acceptable quality  control procedure in place for making these reproductions.
GSK will inform the investigator/institution of the time period for retaining these records 
to comply  with all applicable regu latory  requirements. The minimum retention time will 
meet the strictest standard applicable to a particular site, as dictated b y ICH GCP, any  
institutional requirements, applicable laws or regulations, or GSK standards/procedures , 
otherwise, the minimum re tention period will default to 25 y ears after completion of the 
study  report.
The investigator/institution must notify  GSK of any  changes in the archival 
arrangements, including, but not limited to archival at an off -site facility , transfer of 
ownership of the records in the event the investigator leaves the site. 
11.4. Qualit y assurance
To ensure compliance with GCP and all applicable regulatory  requirements, GSK may  
conduct a qualit y assurance audit. Regulatory agencies may  also conduct a regulatory  
inspection of this study . Such audits/inspections can occur at any  time during or after 
completion of the study. If an audit or inspection occurs, the investigator and institution 
agree to allow the auditor/inspector direct access to all relevant documents and to allocate 
his/her time and the time of his/her staff to the auditor/inspector to discuss findings and 
any relevant issues.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 9111.5. Posting of information on publicly  available clinical trial 
registers and publication policy
GSK assures that the key design elements of this protocol will be posted on the GSK 
website and in publicly  accessible da tabase(s) such as clinicaltrials.gov, in compliance 
with the current regulations.
GSK also assures that results of this study  will be posted on the GSK website and in 
publicly  accessible regulatory  registry (ies) within the required time- frame, in complianc e 
with the current regulations. The minimal requirement is to have primary  endpoint 
summary  results disclosed at latest 12 months post primary  completion date (PCD) and to 
have secondary  endpoint disclosed at latest 12 months after the last subject last visit 
(LSLV)as described in the protocol.
As per EU regulation, summaries of the results of GSK interventional studies (phase I-
IV) in adult population conducted in at least one EU member state will be posted on 
publicly  available EMA registers within 12 mo nths of EoS (as defined in the protocol) in 
the concerned EU member state. However, where, for scientific reasons detailed in the 
protocol, it is not possible to submit a summary  of the results one y earin the concerned 
EU member state , the summary  of results shall be submitted as soon as it is available. In 
this case, the protocol shall specify  when the results are going to be submitted, together 
with a justification . 
GSK also aims to publish the results of these studies in searchable, peer reviewed 
scien tific literature and follows the guidance from the I nternational Committee of 
Medical Journal Editors.
11.6. Provision of study  results to investigators
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the study  report. The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a GSK site or other mutually -
agreeable location.
GSK Biologicals will also provide the investigator with the full summary  of the study  
results. The investigator is encouraged to share the summary  results with the study  
subjects, as appropriate.
11.7. Data Sharing
Under the framework of the SHARE initiative, resu lts of GSK studies may  be combined 
with non- GSK studies, to investigate further about the study  product(s) and other 
product(s), and /or the disease/condition under investigation and related diseases and 
conditions.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 9212. COUNTRY SPECIFIC REQUIREMENTS
12.1. German y
Explanatory  statement concerning Gender Distribution
(Article 7, paragraph 2 (12) of the German GCP ORDER)
EudraCT Number: 2017 -001220-22
Study Identifier: 204487 (ZOSTER -059 PRI )
Compound Number: GSK1437173A
Title of Study: A Phase IIIB, randomized, open -label, multicenter clinical trial to 
assess the immunogenicity and safety of GSK Biologicals‚Äô Herpes 
Zoster vaccine GSK1437173A when co -administered with 
Prevenar13‚Ñ¢in adults aged 50 years and older .
There is no intention to conduct specific anal yses investigating the relationship between 
gender of subjects and the immunogenicit y and safety of GSK Biologicals‚Äô lyophilized 
formulation of the Herpes Zoster (HZ) subunit (HZ/su) vaccine (GSK1437173A ). The 
ratio of male to female subjects recruited into study  Zoster -059 PRI is expected to be in 
line with the demographics of the population aged 50 years and older in the Member 
State.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 9313. REFERENCES
Centers for Disease Control and Prevention Metropolitan Atlanta C ongenital Defects 
Program (CDC MACDP) guidelines. Birth defects and genetic diseases branch 6 -digit 
code for reportable congenital anomalies; 
http://www.cdc.gov/ncbddd/birthdefects/documents/MACDPcode0807.pdf
Chlibek R, Bay as JM, Collins H, de la Pinta ML R, Ledent E, Mols JF, et al. Safety  and 
Immunogenicit y of an AS01- adjuvanted Varicella -zoster Virus Subunit Candidate 
Vaccine Against Herpes Zoster in Adults ‚â•50 Years of Age. J Infect Dis . 2013; 
208(12):1953-61.
Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH, et al. 
Safety  and immunogenicity  of three different formulations of an adjuvanted varicella -
zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled 
study . Vaccine . 2014 3/26/;32(15):1745-53.
Chua JV, Chen WH. Herpes zoster vaccine for the elderl y: boosting immunity . Aging 
health . 2010;6(2):169 -176.
Cunningham , AL; Lal, H; Kovac, M; et al. Efficacy  of the Herpes Zoster Subunit 
Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016, 375 (11), 1019 -1032.
Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of 
Herpes Zoster. Clin Infect Dis. 2007;44 Suppl 1:S1-26.
EMA Guideline on the exposure to medicinal products during pregnancy : need for post-
authorization data (Doc. Ref. EMEA/CHMP/313666/2005 ) ‚Äòadopted at Community  level 
in May  2006);
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_ g
uideline/2009/11/W C500011303.pdf
EMA Prevenar13 pneumococcal poly saccharide conjugate vaccine (13 -valent, adsorbed) 
(Doc. Ref. EMEA/H/C/001104/II/0028), 2011 
http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Assessment_Report_ -_Variation/human/001104/WC500119784.pdf
FDA , U.S. Department of Health and Human Services, Center for Biologics Evaluation 
and Research. Guidance for Industry : Toxicity  Grading Scale for Healthy  Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Version of 
September 2007.
Kawai K, Gebremeskel BG et al. Systematic review of incidence and complications of 
Herpes Zoster : towards a global perspective. BMJ Open . 2014; 4:e004833.
LalH, Cunningham AL, Godeaux O et al. Efficacy  of an Adjuvanted Herpes Zoster 
Subunit Vaccine in Older Adults. N Engl J Med. 2015; 372:2087-2096. 204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 94National Network for Immunization Information (NNii). Herpes Zoster. Updated: April 
2008. http://www.immunizationinfo.org/vaccines/shingles -herpes- zoster. Accessed on 17 
November 2012.
Oxman MN, L evin MJ, Johnson GR, et al. Shingles Prevention Study  Group. A vaccine 
to prevent Herpes Zoster and postherpetic neuralgia in older adults. N Engl J Med.
2005;352:2271‚Äì2284.
Romero- Steiner S, L ibutti D, Pais LB et al. Standardization of an Opsonophagocy tic 
Assay  for the Measurement of Functional Antibody  Activity  against Streptococcus 
pneumoniae Using Differentiated HL -60 Cells. Clin Diagn Lab I mmunol . 1997;4(4):415 -
422.
Sperber SJ, Smith BV, Hay den FG. Serologic response and reactogenicity  to booster 
immunization of healthy  seropositive adults with live or inactivated varicella vaccine. 
Antiviral Res . 1992;17:213‚Äì222.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 95APPENDIX A LABORA TORY ASSAYS
Specific antibody measurements:
Anti -gE ELISA: Anti- gE antibody  concentrations will be measured using an anti -gE 
ELISA. Diluted blood serum samples of study  subjects will be added to microtiter wells 
pre-coated with gE antigen. Secondary  peroxidase -conjugated anti- human Abs will be 
added, which bind to the primary  human anti -gE Abs. After incubation of the microtiter 
wells with a chromogen substrate solution, the enzymatic reaction will be stopped. 
Optical densities will be recorded and anti- gE antibody  concentrations are calculated 
from a standard curve. The assay  cut-off is 97 mIU/mL . 
(Amended 30 January 2018)
Pneumococcal serotype antibodies OPA : Opsonophagocy tic activity  for antibodies 
against each of the pneumococc al serot ype will be measured b yan opsonophagocy tosis 
mulitplex killing -assay  (MOPA) using the HL 60 cell line as the phagocy tic effector cell 
[Romero-Steiner , 1997]. The results will be presented as the dilution of serum (opsonic 
titer) able to sustain 50% killing of live pneumococci under the assay  conditions.204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 96APPENDIX B CLINICA L LA BORATORIES
Table 24 GSK Biologicals‚Äô laboratories
(Amended 30 January 2018)
Laboratory Address
GSK Biological‚Äôs Clinical Laboratory 
Sciences, Rixensart Rue de l'Institut, 89 -B-1330 Rixensart ‚ÄìBelgium 
Table 25 Outsourced laboratories
Laboratory Address
University of Alabama at 
BirminghamPathology Department of Professor, Moon H. 
Nahm, M.D, WHO Pneumococcal Serology 
Reference Laboratory, The University of Alabama 
at Birmingham, Bevill Building, Room 614 (BBRB 
614), 845 19th Street South, Birmingham AL, 
35294
Q2Solutions Clinical Trials (US) 27027 Tourney Road, Suite 2E
Valencia, CA 91355
USA
Q2Solutions Clinical Trials (UK) Unit B1, Parkway West Industrial Estate
Cranford Lane ‚Äì Heston, 
Middlesex TW5 9QA
UK204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIAL
204487 (ZOSTER-059 PRI)
Protocol Amendment 2 Final
30-JAN-2018 97APPENDIX C AMENDMENTS AND ADMINISTRATIVE 
CHANGES TO THE PROTOCOL
GlaxoSmithKline Biologicals
Vaccine Value & Health Science (VVHS)
Protocol Amendment 1
eTrack study number 
and Abbreviated Title204487 (ZOSTER-059 PRI)
EudraCT number 2017-001220-22
Amendment number: Amendment 1
Amendment date: 30 October 2017
Co-ordinating author: , Scientific Writer, contractor for GSK 
Biologicals
Rationale/background for changes:
!Following the initial approval of the GlaxoSmithKline (GSK) Biologicals‚Äô HZ/su 
vaccine, this protocol was amended to indicate that the Trademark is Shingrix .I n  
addition, the term ‚Äúcandidate‚Äù vaccine has been replaced by ‚Äústudy‚Äù vaccine throughout the protocol in Sections 1.1, 1.3, 5.8.5 and 6.1; and the term ‚Äúinvestigational‚Äù vaccine has been replaced by ‚Äústudy‚Äù vaccine in Sections 1.3.1 and 1.3.3.
Amended text has been included in bold italics and deleted text in strikethrough in 
the following sections:
TRADEMARKS:
Trademarks of the GSK group of companies Generic description
Shingrix Zoster Vaccine Recombinant, Adjuvanted
Section 1.1 1.1 Background:
GlaxoSmithKline (GSK) Biologicals‚Äô candidate study vaccine (Shingrix) for the 
prevention of HZ is a recombinant subunit (su) vaccine consisting of VZV glycoprotein E 
(gE) as antigen and an adjuvant system AS01 B. It has been evaluated in several studies in 
healthy adults and shown to elicit strong cellular and humoral immune responses. The safety and reactogenicity profile of the candidate study vaccine was also acceptable.
Please refer to the current Investigator Brochure (IB) for information regarding the pre-
clinical and clinical studies of GSK Biologicals‚Äô candidate study HZ/su vaccine._3URWRFRO$PHQGPHQW-DQ_70)_
PPD
CONFIDENTIAL
204487 (ZOSTER-059 PRI)
Protocol Amendment 2 Final
30-JAN-2018 99GlaxoSmithKline Biologicals
Vaccine Value & Health Science (VVHS)
Protocol Amendment 2
eTrack study number 
and Abbreviated Title204487 (ZOSTER-059 PRI)
EudraCT number 2017-001220-22
Amendment number: Amendment 2
Amendment date: 30 January 2018
Co-ordinating author: , Scientific Writer, contractor for GSK 
Biologicals
Contributing authors ! , Clinical and Epidemiology 
Scientist G Clinical Research and Development 
Lead, Business & Decision Life Sciences for GSK 
Biologicals
! , Clinical and Epidemiology Project 
Leader
! , Study Delivery Lead, Synteract Inc. 
for GSK Biologicals
! , Global Regulatory Affairs
! , Clinical Safety 
representative
!  Study Data Manager (Tata 
Consultancy Services for GSK Biologicals)_3URWRFRO$PHQGPHQW-DQ_70)_
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CONFIDENTIAL
204487 (ZOSTER-059 PRI)
Protocol Amendment 2 Final
30-JAN-2018 100Rationale/background for changes:
Major change
!This amendment is in response to the Center for Biologics Evaluation and 
Research (CBER) comments on Protocol Amendment 1, received on 09-January-
2018, requesting clarification on 1. the adjustment for baseline titers in the computation of the Multiplex Opsonophagocytosis Assay (MOPA) Geometric Mean Titers (GMT) ratios (Section 10.7.2) and 2. time points for primary evaluations on co-primary immunogenicity objectives (Section 10.10.1).
Other changes
!The tradename for 
pneumococcal polysaccharide conjugate vaccine (13-valent adsorbed)
in Canada has been corrected to Prevnar13 from Prevenar13.
!The laboratory to be used for MOPA testing has been selected and is presented in 
Appendix B.
!A typographical error in the estimated number of subjects in each age strata and 
study group has been corrected. Table 4 reflects the correct number of subjects for age stratification.
Amended text has been included in bold italics and deleted text in strikethrough in 
the following sections:
Protocol Amendment 2 Sponsor Signatory Approval
Sponsor signatory
Clinical and Epidemiology Project Leader (CEPL),
Zoster Program, Beligian Research and Development 
Center (RDC)
Clinical and Epidemiology Project Leader, 
Zoster Program, US Research and Development Center (RDC)
List of abbreviations:
CBER: Center for Biologics Evaluation and Research 
CRO: Contract Research Organization_3URWRFRO$PHQGPHQW-DQ_70)_
PPD
PPD
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 101Trademark s
Trademarks not owned by the GSK group of 
companies Generic description
Prevenar13 (Trade name for Canada, Germany 
and Estonia)/ Prevnar13 Trade name for 
Canada and United States)*
Wyeth Pharmaceuticals Inc./Pfizer Inc.Pneumococcal polysaccharide conjugate 
vaccine (13 -valent adsorbed)
Section 4.1 Number of subjects/centers
Table 4 Age Stratification
Group Description Estimated number of subjects
Co-AdSubjects 50 to 59 YOA 342171
Subjects 60 to 69 YOA 342171
Subjects ÔÇ≥70 YOA 228 114
ControlSubjects 50 to 59 YOA 342171
Subjects 60 to 69 YOA 342171
Subjects ÔÇ≥70 YOA 228 114
YOA: years of age.
Section 5.8.3 Laboratory assays
Serological assay s for the determination of pneumococcal serot ype antibodies will be 
performed b y multiplex opsonophagocy tosis assay  (MOPA) at a GSK Biologicals‚Äô 
laboratory  or in a laboratory  designated by  GSK Biologicals using standardized and 
validated procedures (refer to Table 11).
The GSK Biologicals‚Äô / contract research organizations‚Äô (CRO) clinical laboratories 
have established a Quality  System supported b y procedures. The acti vities of GSK 
Biologicals‚Äô / CROs‚Äô clinical laboratories are audited regularly  for qualit y assessment by 
an internal (sponsor -dependent) but laboratory -independent Quality  Department. Clinical 
laboratories contracted by GSK also conform to Good Laboratory P ractice guidelines 
and operat ein compliance with regulatory standards.
Section 10.7.2 Statistical considerations for confirmatory objectives
Family  3:
The 95% CI of the group MOPA GMT ratios will be computed using an analy sis of 
variance ( ANC OVA )model on the log10 transformation of the concentrations/ titers. The 
pre-vaccination log -transformed antibody titers will be included as a continuous 
covariate .The AN COVA model will include the vaccine group and age strata as fixed 
effects .204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0
CONFIDENTIA L
204487 (ZOSTER- 059 PRI)
Protocol Amendm ent 2 Final
30-JAN -2018 102Section 10.10 .1 Sequence of analyses
The anal ysis will be performed in the following steps:
1.Analy ses after end of active phase at Visit Month 3 for Co Ad group and Visit 
Month 5 for Control group will be performed on data as clean as possible, in order to 
explore the d emograph y as well as reactogenicity  and safet y. Anal ysis on the 
humoral response may  also be performed at this point in time if the data is available. .
These data will also be available for the purpose of public data disclosure .
Analysis of the co -primary immunogenicity objectives will be performed at the end 
of the active phase on data as clean as possible. A confirmatory re -analysis will be 
done at the end of the study using the final database. In addition, analyses of 
secondary objectives will also be performed at the end of the active phase.
2.Analy ses on immunogenicity  and safet
ydata will be performed when all data up to 
study  end (i.e., phone contact at Month 14 for Co-Ad group and phone contact at 
Month 16 for Control group) will be available and cleaned. After the study  
completion, results from both analy ses will be presented in a single study  report.
APPENDIX A LABORATORY ASSAYS
Specific antibod y measurements:
Anti -gE ELISA: Anti- gE antibody  concentrations will be measured using an anti -gE 
ELISA. Diluted blood serum samples of study  subjects will be added to microtiter wells 
pre-coated with gE antigen. Secondary  peroxidase -conjugated anti- human Abs will be 
added, which bind to the primary  human anti -gE Abs. After incubation of the microtiter 
wells with a chromogen substrate solution, the enzymatic reaction will be stopped. 
Optical densities will be recorded and anti -gE antibody  concentrations are calculated 
from a standard curve. The assay  cut-off is 97 mIU/mL . The assay  will be performed on 
human serum at GSK Biologicals‚Äô laboratory  or another laboratory  designated by  GSK 
Biologicals.
APPENDIX B CLINICAL LABORATORIES
Table 24 GSK Biologicals‚Äô laboratories
Laboratory Address
GSK Biological‚Äôs Clinical Laboratory 
Sciences, Rixensart Rue de l'Institut, 89 -B-1330 Rixensart ‚ÄìBelgium 
GSK Biological‚Äôs Clinical Laboratory 
Sciences, Wavre Nord Noir EpineAvenue Fleming, 20 B1300 Wavre Belgium204487 | Protocol Amendment 2 30 Jan 2018 | TMF-994517 | 2.0